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THREE-DIMENSIONAL HUMAN NEURAL STEM CELL CULTURE
FOR HIGH-THROUGHPUT ASSESSMENT OF DEVELOPMENTAL
NEUROTOXICITY
PRANAV JOSHI
ABSTRACT
Only a few hundred of compounds, among tens of thousands of commercially available
compounds, have been tested for developmental neurotoxicity (DNT) due to the limitations
of current guidelines for DNT which are based entirely on in vivo experiments. In vivo
studies are highly expensive and time-consuming, which often do not correlate to human
outcomes. There is a key gap in our ability to predict in vivo outcomes accurately and
robustly using in vitro assays. This is particularly the case for predicting the toxicity of
chemicals on the developing human brains. Conventional in vitro assays are typically
performed in two-dimensional (2D) cell culture systems and use cytotoxicity assays that
do not provide the information on mechanisms of toxicity. High-content imaging (HCI)
assays performed on three-dimensional (3D) cell cultures can provide better understanding
of mechanisms of toxicity needed to predict DNT in humans. However, current 3D cell
culture systems lack the throughput required for screening DNT against a large number of
chemicals. Thus, there is a need for cost-effective, high-throughput, alternative in vitro test
methods based on mechanisms of toxicity.
In this study, we first developed a miniaturized, 3D human NSC culture with
ReNcell VM on the micropillar chip platform and established a high-throughput promoterreporter assay system using recombinant lentiviruses on human NSC spheroids to assess
vii

cell viability, self-renewal, and differentiation. Next, we identified major ion channels and
ABC-transporters expressed in ReNcell VM via RNA-seq analysis and established highthroughput ion channel and ABC-transporter assays in 3D-cultured ReNcell VM on the
384-pillar plate. In the third step, we established high-content imaging (HCI) assays in 3Dcultured ReNcell VM with multiple assays which were tested with four model compounds.
Finally, we established a high-throughput metabolism-mediated neurotoxicity testing
system by combining 3D-cultured ReNcell VM on the 384PillarPlate and HepaRG
spheroids in a ULA 384-well plate. Alternative in vitro systems for high-throughput
neurotoxicity assessment established in this study will enable researchers to screen a library
of test compounds with high confidence in terms of predictability of adverse reactions in
vivo from those compounds.
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CHAPTER I
INTRODUCTION
1.1. Current issues on developmental neurotoxicity
The disabilities associated with the functioning of developing nervous system is
known as neurodevelopmental disorders which include disabilities such as attention
deficit/hyperactivity disorders (ADHD), autism, cerebral palsy, intellectual disability
(mental retardation), and learning disabilities. One out of six children in US are diagnosed
with a neurodevelopmental disorder and ADHD alone affects 14% of the children born in
US each year. Neurodevelopmental disorders can occur due to combination of genetic,
biological, psychosocial and environmental risk factors [1]. Out of all the cases of
neurodevelopmental disorders, genetic factors contribute to nearly 30-40% of it whereas
rest of the cases are more likely attributed to environmental risk factors [2].
Environmental risk factors such as use of alcohol, tobacco, and opioids during pregnancy,
premature birth, and prenatal or childhood exposure to environmental toxicants can all
contribute towards the above mentioned disorders [1]. According to US National Research
Council, 3% of developmental disabilities are directly related to environmental exposure
of toxic chemicals while another 25 % is the result of interaction between other
environmental factors and genetic susceptibility of individuals [3].
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Developmental neurotoxicity (DNT) can be defined as any adverse effect in the
structure or function of the nervous system resulting from chemical exposure during the
prenatal or gestational period [4], [5]. The developing nervous system is known to be more
vulnerable to chemical exposure as compared to the adult nervous system due to the
complexity of human brain development consisting of various processes such as
proliferation, differentiation, migration, cell to cell communication that must take place in
a highly controlled time frame. The blood-brain barrier (BBB) which protects the adult
brain is also not completely developed until about 6 months after birth. Moreover, the
susceptibility of developing brain to environmental chemicals is further augmented by their
increased exposures, absorption rates, and decreased ability to detoxify as compared to
fully developed adult brain [3], [6].
Despite the potential vulnerability of developing brain to the environmental
toxicants, there is only a small amount of data available for developmental neurotoxicity.
Out of more than 200 chemicals known to be neurotoxic, only 5 of these have been
documented to be the cause of developmental neurotoxicity. However, it is highly likely
that many of these chemicals are capable of causing developmental neurotoxicity [2], [7].
This lack of documentation is mainly because there is no a priori requirement for chemicals
to be tested for DNT effects prior to their registration and use under the present regulation.
DNT study is not a mandatory requirement in the USA for pesticides, biocides,
pharmaceuticals or industrial chemicals and is carried out only when relevant observations
are made in other studies based on structure activity relationships or evidence of
neurotoxicity in standard in vivo adult, developmental or reproduction studies either after
acute exposure, or sub-acute and sub-chronic or chronic exposure [6]–[9].
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Identification of chemicals for their potential to cause DNT is primarily based on
the guidelines from organization for economic co-operation and development (OECD),
OECD TG 426 (an update to the US EPA DNT guideline (OPPTS 8706300, EPA 712-C98-239)) and OECD TG 443 guidelines. These guidelines require neurobehavioral
determination of cognitive, sensory and motor functions accompanied by morphometric
and histopathological evaluation of the brain and are entirely based on animal studies
performed mainly in rat. Since, the in vivo studies are extremely resource intensive in terms
of the number of animals used, time and overall cost [10], these guidelines have been used
only for a limited number of chemicals (approximately 120) [11], [12]. In addition, in vivo
studies are unsuitable for screening large numbers of chemicals, due to the use of large
number of animals and long duration of tests [7].
Identification of chemical’s toxic effect on developing brain is an important first
step towards prevention of neurodevelopmental disorders thereby restricting the use and
limiting the exposure of those chemicals [3]. Therefore, an alternative approach to identify
DNT chemicals and further guide chemical prioritization for testing in a rapid and costeffective manner needs to be developed [6].
1.2. Conventional methods of developmental neurotoxicity assessment: In vivo vs. In
vitro models
Current guidelines for DNT based on in vivo studies are ethically questionable,
time-consuming, and highly expensive. Testing one compound requires about 700 rodents,
lasts up to 12 months and costs up to one million USD [10], [11], [13]. However, even with
the time-consuming and expensive in vivo studies, the predictability of human
neurotoxicity is still questionable due to the lack of pharmaco-/toxicodynamics relation of
the developing brain of rodents with humans [14], [15] and concern over species-specific
3

differences in the extrapolation of human neurotoxicity [7], [16], [17]. Studies have shown
that toxicity testing in rodents are predictive of human toxicity in less than only half of the
cases [18] and mouse brains differ in the temporal aspects of neurogenesis from human
brains [19], which is important for developmental neurotoxicity (DNT) [9].
Reliable, fast and efficient screening and assessment tools are needed to improve the
identification, and evaluation of chemicals with the potential to induce DNT in shorter
time, cost-efficient manner, and with human-specific toxicity pathways [7], [20]. This
requires a major shift from the current OECD guidelines with animal experiments towards
new in vitro approaches to identify the mechanism of toxicity [9], [21], [22]. Replacing the
OECD guidelines requires an in vitro test battery of DNT responses to provide data
predicting the adverse effect of chemicals on human health [23], [24]. Prevention of
neurodevelopmental disorders has been severely restricted due to the lack of in vitro testing
of environmental pollutants and toxic chemicals. Moreover, mimicking the complexity of
the central nervous system (CNS) and modeling of functional disturbances manifested by
neurotoxicity in vitro pose a serious challenge for in vitro assessment of neurotoxicity [12].
Therefore, efforts have been made to overcome these hurdles to some extent by developing
in vitro neurotoxicity testing system in platforms such as 96-well plates [25], cellular
microarrays [26], and microfluidic devices [27].
1.2.1. Well Plate Assays
Several in vitro models for neurotoxicity testing have been developed in 96-well
plates due to the ease of use and flexibility to test different culture conditions. Neurotoxic
effect of various toxicants including heavy metals [28], insecticides [29], nanoparticles
[30], and therapeutic drugs [25] and their differences among human and mouse models
4

have been widely investigated using the 96-well plate platform [30], [31]. For example,
Chang et al. reported that human NSCs treated with MeHg underwent caspase-dependent
apoptosis, autophagy, and inhibition of differentiation [32]. Similarly, Zychowicz et al.
demonstrated the effect of MeHg on viability, proliferation, and differentiation of NSCs,
cultured on various bio-functionalized surfaces coated with fibronectin, vitronectin, and
poly-L-lysine (PLL) in 96t-well plate. All three endpoints were shown to be significantly
inhibited in cells attached to PLL, whereas cells attached to fibronectin and vitronectin
were shown to be less sensitive to MeHg toxicity at certain doses [28]. Likewise, the effects
of insecticides and nanoparticles on human NSCs have also been well studied using this
platform. For example, Lee et al. evaluated the mechanisms involved in neurotoxic effects
of chlorpyrifos (CPF) on human neural progenitor cells (hNPCs) for the first time. The
authors demonstrated the effect of oxidative stress in CPF-induced cell death via activation
of NF-kB mediated p53 pathway [29]. Liu et al. investigated the neurotoxic effects of silver
nanoparticles (Ag-NPs) in human and rat embryonic NSCs by evaluating endpoints such
as viability, proliferation, apoptosis, and oxidative stress. Similar neurotoxic effect of AgNPs in both human and rat NSCs in dose and exposure-time dependent manner were
observed [30].
1.2.2. Microfluidic Assays
A microfluidic device contains an array of microchannels for cell culture with
multiple inlets and outlets providing access to desired reagents (Figure 1.1). Microfluidic
devices enable miniaturized biochemical assays (also known as “lab on a chip”) with the
advantage of culturing cells under various flow conditions in a single chip. This platform
has been implemented for various applications such as in vitro drug toxicity testing [33],
5

anticancer drug screening [34], and intracellular signaling studies [35], [36]. It has also
been commonly used to study the self-renewal [37], differentiation [38]–[40], and
migration [41], [42]. For example, Lee et al. [38] demonstrated the utility of microfluidics
technology for the study of neurite outgrowth and axonal guidance of neural cells derived
from human embryonic stem cells (hESCs). H9 hESCs were differentiated into neuronal
lineages and the migration of axons into the microchannels were studied via pre-neural cell
marker fluorescent staining such as TUJ1 (neuron-specific class III beta-tubulin) [38].

PDMS

Medium inlet

(i)

Cell inlet
(ii)

Step 1

PDMS

Cell Step 2

Step 3

Glass
slide

Medium

Glass slide Medium outlet
Cell outlet

Figure 1.1. Microfluidic device. (i) Top view of a bilayer microfluidic chip fabricated with
PDMS on top of a glass slide. Several inlet and outlet channels provide parallel access to cell
suspension, growth medium and other reagents. (ii) Overview of the cell culture process in the
microfluidic device: (Step 1) Bi-layer chip is fabricated with PDMS containing several
channels on top of a glass slide. (Step 2) A mixture of cells and hydrogel precursor is fed from
the cell inlet channel. (Step 3) A growth medium is supplied from the medium inlet channel
for cell culture. (Farrel, K., Joshi, P., Roth, A., Kothapalli, C.R., Lee, M.Y., High-throughput
screening of toxic chemicals on neural stem cells, Human Stem Cell Toxicology, Royal Society of
Chemistry, 31-63 (2016))
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Similarly, an advanced microfluidic platform capable of generating stable
concentration gradient was used for studying the migration of NSCs within stable linear
cytokine stromal cell-derived factor 1α (C-X-C motif chemokine 12, or CXCL12) gradients
[41]. Other work, which includes the capability of brain-derived neurotrophic factor
(BDNF) to direct chemotaxis of NSCs towards CXCL12 without affecting the migration
speed, has been demonstrated. This effect was mediated through the CXCL12/ C-X-C
chemokine receptor type 4 (CXCR4) system [41]. In addition, Yang et al. reported a
microfluidic array platform providing in vivo-like 3D niche conditions for the study of NSC
self-renewal and differentiation. Four combinations of ECM proteins were used to develop
the in vivo-like 3D niche environment under low oxygen (i.e., hypoxic) culture conditions,
and its effects on hNSC self-renewal and differentiation were investigated [37]. The
application of microfluidic devices have been demonstrated in wide areas of neuroscience
research such as the study of neurite response to growth factor gradient [43], testing of
neurotoxic effect of amyloid beta proteins [27], neurotoxicity testing in co-culture of
neurons and astrocytes [44]. However, these studies were all based on the use of primary
neurons and studies implementing NSCs are limited only to the investigation of stem cell
differentiation and migration. Issues such as air bubble trapping and clogging of
microchannels from cells also pose limitations for high-throughput application of this
platform. For these reasons, limited work specific to developmental neurotoxicity has been
applied using this platform.
1.2.3. Cellular Microarrays
Cellular microarray technology is a miniaturized platform consisting of 3D cell
spots encapsulated in a hydrogel matrix on glass slides or plastic chips (Figure 1.2). The
7

microarray platforms have already found their niche in various applications such as in vitro
testing of drug candidates and their metabolites for metabolism-induced toxicity [45], [46],
screening of anticancer drug efficacy [47], and stem cell differentiation and toxicity
[48][49]. For example, Fernandes et al. demonstrated the utility of 3D cell-based
microarray platform for the study of embryonic stem cell differentiation with the
combination of retinoic acid and fibroblast growth factor-4 (FGF-4) [48]. However, it is
only recently that this platform was applied for neurotoxicity testing with hNSCs [26][49].
(A)

Cell spots in hydrogel

PS-MA
coating

Ceramic
tip
BaCl2/Poly-Llysine spots

Glass slide

(B)

Cells encapsulated in hydrogel

Micropillar chip

Hydrogel spots
with cells (50 nL)

Sandwiching
chips

Hydrogel
bottom

Microwell chip

Media, viruses, proteins
compounds, etc. (800 nL)
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Figure 1.2. (A) Cellular microarrays on a functionalized glass slide. A mixture of cells
and hydrogel precursor is printed on a glass slide coated with poly(styrene-co-maleic anh
ydride) (PS-MA). Various polymer coating is done on top of the PS-MA coating to attach
different hydrogels to the glass slide. Cells are encapsulated in a hydrogel matrix, forming
3D structures after gelation (which occurs via various mechanisms). (B) Cellular microa
rrays on a micropillar/microwell chip platform. Cells mixed with hydrogel are printed
on top of the micropillar chip. After gelation, the micropillar chip containing cells encaps
ulated in hydrogel is sandwiched with a complementary microwell chip containing growt
h media or other reagents. (Farrel, K., Joshi, P., Roth, A., Kothapalli, C.R., Lee, M.Y., High-thr
oughput screening of toxic chemicals on neural stem cells, Human Stem Cell Toxicology, Royal S
ociety of Chemistry, 31-63 (2016))

Apart from the above mentioned platforms, toxicity testing in NSCs have been performed
using various other culture platforms such as cell-culture flasks [50] and petri dishes [51].
The convenience of culturing NSCs and the flexibility to modify the culture conditions m
ay drive researchers to use simple cell culture flasks and dishes. For example, Demir and
Laywell [50] used culture flasks for testing neurotoxicity of azidothymidine (AZT), an an
ti-HIV drug, in which neural colony-forming cell (NCFC) assay was performed along wit
h drug treatment. Long-term administration of AZT was found to be associated with pertu
rbations in both proliferative capacity and neurogenesis [50]. In another example, Bai et a
l. investigated the neurotoxic effects of ketamine in hNSCs and neurons on petri dishes an
d demonstrated that short term exposure of ketamine increased hNSC proliferation, where
as long-term exposure caused apoptosis in neurons without affecting hNSCs [51].

1.3.Representative cell-based assays for neurotoxicity assessment
Evaluation of DNT in an in vitro system possess challenge due to the dependency
of adverse effect of toxicants on not only the dosage and duration of exposure but also on
the developmental stage of the brain at the time of exposure [6], [52]. In addition,
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mimicking the complex physiological organization of the nervous system with network of
several cell types in an in vitro system is a major hurdle in implementing in vitro cell-based
assay systems for DNT testing [53]. For any in vitro model to be highly predictive, it should
recapitulate the basic processes involved in CNS development such as proliferation,
migration, differentiation, and synaptogenesis. Therefore, endpoints such as cell viability,
apoptosis, proliferation, differentiation, migration, and neurite outgrowth are commonly
used to evaluate neurotoxicity [25], [28], [30], [54].
Current in vitro methods for neurotoxicity testing have been developed
utilizing various cellular models such as immortalized cell lines, neural stem cells (NSCs),
and primary cells from both rodent and human species. Primary cells are limited in their
ability to proliferate and differentiate, and transformed cell lines derived from tumors such
as PC12 cell lines (rat pheochromocytoma) and B50 cell lines (rat neuroblastoma) do not
represent the native neural cells [55]. In addition, species-specific differences exist between
rodents and humans in terms of sensitivity to toxins [25], [30]. Therefore, human NSCs are
highly desirable for developing a predictive model system for developmental neurotoxicity
assay due to its ability to self-renew and to differentiate into neurons, astrocytes and
oligodendrocytes [8], [26], [56]. Various assays have been developed to evaluate
neurotoxicity in NSCs which are summarized in Table 1.
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Table 1. Conventional in vitro assays used for neurotoxicity screening in NSCs.

Application

Assays/Endpoints

Reference

Generation and assessment of
neurons for drug screening

Differentiation, cell viability,
mitochondria, nuclei tracking

[57]

HTS of neurotoxic compound

Cell viability, cellular morphology

[25]

Evaluate the influence of cell-ECM
interaction on response to toxic
compounds

Viability, proliferation, differentiation

[28]

Determining the toxic effects of AgNPs in NSCs

Proliferation, western blot analysis for
apoptosis, autophagy, differentiation
marker
Viability, cytotoxicity, intracellular
ROS and malondialdehyde (MDA)
measurement, nuclear morphology,
western blot analysis
Viability, cytotoxicity, proliferation,
apoptosis, oxidative stress

HTS of chemical-induced toxicity

Proliferation, apoptosis, viability

[31]

Quantification of neurite growth in
high-density cultures for toxicity
detection

Viability, algorithm for neurite
identification, western blot analysis

[54]

Investigating MeHg-induced
cytotoxicity pathway
Investigating the mechanism
involved in CPF-induced
neurotoxicity in NSC

[32]

[29]

[30]

Viability, proliferation, western blot
HTS of neurotoxic compounds
analysis of marker proteins,
[26]
immunofluorescence assay
NCFC assay, neurosphere assay,
Evaluate the neurotoxic effect of
proliferation, neurogenesis, SAβGal+
[50]
AZT drug
labeling
Abbreviations: extracellular matrix (ECM), methylmercury (MeHg), chlorpyrifos (CPF), r
eactive oxygen species (ROS), silver nanoparticles (Ag-NP), azidothymidine (AZT), neur
al colony-forming cell (NCFC), senescence-associated β-galactosidase (SAβGal) (Farrel,
K., Joshi, P., Roth, A., Kothapalli, C.R., Lee, M.Y., High-throughput screening of toxic chemicals
on neural stem cells, Human Stem Cell Toxicology, Royal Society of Chemistry, 31-63 (2016))

1.4. Neural stem cells (NSCs) and 3D culture
Human in vitro neuronal cultures derived from NSCs have been intensively studied
over the past decade as they are self-renewable, and can be differentiated into several
neuronal and glial cell types [6], [56]. NSCs have been identified in several regions of the
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human brain in all stages of development [58]. A substantial population of NSCs are present
in ventricular and subventricular zones (VZ and SVZ, respectively). Studies in rat
embryogenesis CNS models have shown that NSCs compose most of the neural crest and
around 50% of the spinal neural tube [59]. NSCs have the capability to self-renew and
differentiate into neurons, astrocytes, and oligodendrocytes and therefore play a critical
role in the developing embryonic nervous system where the ability for self-renewal is
important for normal functions, such as learning, memory, and response to injuries. NSCs
expand and maintain an undifferentiated phenotype in the presence of epidermal growth
factor (EGF) and/or basic fibroblast growth factor (bFGF), and differentiate into neuronal
and glial lineages upon the removal of these growth factors [60]. The proliferation,
differentiation, and migration of NSCs are crucial in human brain development;
disturbance of which has been linked to neurodevelopmental disorders [8], [61]. Therefore,
NSCs can be used to model neurodegeneration and are considered as the most suitable cells
for DNT testing [62], [63].
NSCs derived from induced pluripotent stem cells (iPSCs), the NIH approved H9
(WA09) hESC line, or cells derived from human fetal brain tissue immortalized via
retroviral transduction with the myc oncogene (e.g., ReNcell VM, ReNcell CX) are
commercially available from vendors including Life Technologies, Alstem, and EMD
Millipore. In addition, NSCs are also directly harvested from either embryonic or adult
mammalian brain tissue using established protocols [64]. Due to the efficient harvesting
and expansion of these cells, they have been successfully implemented as models for in
vitro DNT tests [65]. Moreover, NSCs are highly sensitive to neurotoxicants, as compared
to other neural cell types [53], [66].
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It is now widely accepted that cells cultured in conventional two-dimensional (2D)
systems differ from three-dimensionally (3D) cultured cells in terms of their morphology,
physiology, protein/gene expression, and metabolism [67]–[71]. Stem cells are known to
lose phenotypic properties in 2D monolayer culture due to the lack of intercellular contacts
and interactions thereby restricting the formation of in-vivo like tissue structures [67], [68],
[70], [71]. In addition, important biological cues provided to cells by the ECM in response
to external stimuli are also missing in 2D grown cells.
On the other hand, 3D cell culture have been known to maintain normal cell
function such as differentiation, migration, and proliferation [72], [73] and have further
been shown to recapitulate in vitro brain tissue physiology and microenvironmental
conditions [6], [74], [75]. In addition, complex tissue structures can be developed in
controlled conditions with the combination of 3D cell culture technology and the
knowledge on stem cell differentiation. Efforts have been made towards developing 3D
cell culture platform capable of maintaining specific in vivo-like biochemical and
morphological features of human cells [13]. For example, Pasca et al. generated a
laminated cerebral cortex with spheroid culture of pluripotent stem cells demonstrating
electrophysiologically mature neurons from various cortical layers [76]. Likewise, Kim et
al. developed a model system for characterization of Alzhiemer’s disease using 3D culture
of neural stem cells [77]. Therefore, a 3D cellular model with NSCs enhances the
understanding of the molecular and cellular mechanisms underlying DNT/NT and serves
as a powerful tool for assessing the impact of chemical exposure on developing brain [13],
[78].
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1.5. High-throughput, high-content imaging (HCI) platforms for neurotoxicity
assessment
There is an urgent need to develop in vitro neurotoxicity testing system which are highthroughput, economically-feasible, and highly-predictive [8]. However, due to the
challenge in mimicking the complexity of the CNS, there have been limited development
in terms of high-throughput in vitro assays for screening toxic chemicals for their effect on
developing nervous system. Development of high-throughput screening (HTS) assays
utilizing hNSCs will therefore prove to be beneficial in assessing the chemical toxicity on
stem cells and their differentiated lineages, providing a predictive model system for
evaluating neurotoxicity [26]. Several in vitro cell-based assays have been developed with
NSCs to study the toxic effect of various neurotoxicants; however, only a few of them have
been able to demonstrate HTS capability for neurotoxicity screening. For example, Malik
et al. developed a 96-well in vitro cell-based assay where 2000 compounds including drugs,
natural products, and bioactive compounds were tested on human NSCs and rat cortical
mixed cells with results highlighting species-specific differences in the toxicity of the
compounds [25]. Nearly a hundred of these compounds showed significant toxicity to
hNSCs without affecting rat cortical mixed cells. This HTS assay was built on an in vitro
model developed by Efthymiou et al. to culture human NSCs and differentiate into neurons
and astrocytes for HTS application in drug discovery [57].
Conventional high-throughput cell-based assays implemented for toxicity
screening in NSCs evaluates a single endpoint involved in decreased cellular health or
death. This approach often lacks the ability to provide predictive information of the NSC
responses in vivo against toxic chemicals and drug candidates, which is critical to reduce
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the high attrition rate in downstream drug discovery pipelines and determine the toxicity
of environmental toxicants [67], [79]. Modeling the functional disturbances manifested by
neurotoxicity in vitro possess a big hurdle in developing a highly-predictive assay for
neurotoxicity assessment [12]. Based on the knowledge that impairment in the
development of nervous system is the combined effect of disturbances/impairment in
various neuro-developmental processes/endpoints [13], [80], the screening of large number
of neurotoxic chemicals require characterization of those chemicals based on their
biological activity i.e. the ability to trigger an impairment of specific end points. This can
be achieved by investigating the effects of chemicals at the molecular and cellular level
implementing high-content imaging (HCI) assays with particular emphasis on studying the
mechanisms of neurotoxicity [81]–[85].
HCI assays are high-throughput, automated, cell-based assays that provide
information on multiple properties of individual cells simultaneously by utilizing several
fluorescent dyes thereby enabling a systematic and accurate evaluation of neurotoxicants
[86], [87]. HCI assays are capable of analyzing numerous cellular functions and features
such as cell growth, cell viability/cytotoxicity, nuclear morphology, apoptosis/necrosis,
mitochondrial membrane potential, oxidative stress, intracellular calcium levels, and
glutathione levels at the individual cell level which enables us to understand the mechanism
of action of drug candidate and toxic chemicals [88], [89]. Various fluorescent
probes/reagents are used to label different parameters for example Hoechst 33342 (ex. 361
nm/em. 497 nm) for nuclear morphology and cell count, calcein AM (ex. 495 nm/em. 515
nm) and propidium iodide (PI) (ex. 535 nm/em. 620 nm) for cell viability, tetramethyl
rhodamine methyl ester (TMRM, ex. 545 nm/em. 575 nm) for mitochondrial membrane
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potential (MMP), fluo-4 AM (ex. 490 nm/em. 520 nm) for intracellular calcium levels, YOPRO-1 (ex. 490 nm/em. 510 nm) for apoptosis, monochlorobimane (mBCl, ex. 380 nm/em.
460 nm) for glutathione levels, and H2DCFDA (ex. 495 nm/em. 527 nm) for oxidative
stress damage [88], [90]–[93]. The fluorescent dyes/reagents target specific organelles or
function and does not interfere with global physiological conditions of cells.
HCI assays have been implemented on various cellular models such as primary
cells [94], immortalized cell lines [88], and stem cells [95] for investigating the toxic
effects of various drug compounds, nanoparticles and environmental chemicals in human
organs. Although there has been some progress in developing HCI assays to assess
neurotoxicity, most of the assays are based on differentiated neuronal cell models [96]–
[98] and does not correlate well with potential in vivo neurotoxicity mechanisms.
Furthermore, conventional 3D cell culture systems are not amenable to high-throughput
platform mainly due to difficulty in handling large volume of viscous solutions and
acquisition of 3D-cultured cell images. For example, dispensing the mixture of cell
suspension and viscous hydrogel and changing growth media over time without affecting
the consistency and reproducibility in 96-well plate is a challenging task [70]. Moreover,
the cost of reagents and compounds in conventional 3D culture system limits the number
of assays that can be performed for HCI [99]. Image acquisition and processing of 3D cells
on polymer scaffolds pose significant challenges due to growth of cells in multiple focal
plane. This issue is addressed to some extent with confocal microscopy followed by 3D
image reconstruction, however, with the compromise in throughput. In addition, some
polymer scaffolds are inadequate for imaging due to their opaque nature. Few HCI assays,
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therefore, have been implemented on 3D culture system due to the above-mentioned
limitations of 3D cell culture systems for HTS.
HTS of large libraries of toxic chemicals for prediction of neurotoxicity requires
miniaturization as it offers several advantages such as reduced sample volume, decrease in
cost, and an increase in efficiency over contemporary macro-scale cell culture technology
such as 3D NSC cultures in 96-well plates [46], [47]. Cellular microarrays based on a
micropillar chip and a complementary microwell chip have recently been developed for
high-throughput cell based assays such as 3D culture of mammalian cells, enzymatic
reactions, viral infection, and compound screening [46], [47]. Cellular microarrays on the
chip offers several advantages in HTS of compound libraries assays as they require
extremely small amount of cells, natural and synthetic hydrogels or extracellular matrices
(ECMs), growth factors, compounds, and reagents for 3D cell cultures [46], [47].
Reduction in assay volume and reagent consumption further facilitates the use of expensive
hNSCs, thereby leading to enhanced predictability of in vivo responses towards toxicants
[100]. Moreover, the image acquisition period is shorter and the process in itself becomes
simpler due to the thin depth of focus position of samples, further leading to increased
signal-to-noise ratios [101]. Varieties of cell culture conditions and individual
drugs/mixtures of drugs in combinations can be tested, making it well suited for early stage
HTS of compound libraries. In addition, miniaturized 3D cell culture on the chip can
provide a microenvironment that simulates in vivo ECM conditions, and thus help maintain
biochemical functions and morphological features similar to in vivo human tissues [102].
Therefore, high-throughput microarray platforms with HCI can be an attractive tool for
studying the NSC response against large library of neurotoxicants.
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The goal of our research is to develop 3D bioprinting chip platforms for HTS of
compounds including drug candidates and environmental toxicants for mechanistic
toxicology and chemical metabolism with organotypic cells. Specifically, to overcome the
limitations of existing HTS technologies for neurotoxicity and enhance predictability of
compound toxicity in vivo, we proposed to construct physiologically-relevant cellular
microarrays in 3D using human NSC cultures and elucidate mechanistic toxicity by using
HCI techniques, all in a high-throughput fashion.
The specific aims of this project are to:
1) Develop three-dimensionally (3D) cultured, neural stem cell (NSC) microarrays
for high-throughput assessment of developmental neurotoxicity.
2) Establish high-throughput ion channel and ABC-transporter assays on 3Dcultured NSCs for neurotoxicity assessment.
3) Establish high-content imaging (HCI) assays on 3D NSC microarrays to
investigate mechanistic profiles of toxicity by compounds and their metabolites.

1. Develop three-dimensionally (3D) cultured, neural stem cell (NSC) microarrays
for high-throughput developmental neurotoxicity
We aim to establish 3D culture of NSC with extracellular matrices and synthetic
hydrogels on the chip platform. High-throughput assessment of key variables critical
for growth and induced differentiation of NSCs will be performed on the chip using
recombinant lentiviruses with fluorescent NSC biomarkers.
2. Establish high-throughput ion channel and transporter assays on 3D-cultured
NSCs for the neurotoxicity assessment.
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We aim to establish high-throughput ion channel and transporter assays on 3D NSC
microarrays to evaluate whether model compounds interact with cell surface receptors
such as ion channels and transporters on NSCs.
3. Establish high-content imaging (HCI) assays on 3D-cultured NSCs for the
assessment of mechanistic neurotoxicity by the test compounds and their
metabolites.
We aim to establish HCI assays on 3D NSC microarrays to evaluate toxic effects of
various compounds and their metabolites within NSCs. For this, we will first establish
high-content imaging (HCI) assays in 3D-cultured NSC microarrays for the assessment
of mechanistic neurotoxicity which will be combined with human liver cell spheroids
expressing cytochrome

P450 enzyme to

neurotoxicity.
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2.1. Introduction
Exposure to toxic compounds during early fetal development has been linked to various
neurodevelopmental disorders such as attention deficit disorders, autism, cognitive and
behavioral alterations, and mental retardation [3], [13], [103]. Conventional animal models
for developmental neurotoxicity (DNT) testing are expensive, time-consuming low-
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throughput, subject to genetic and age-related variability, and often poorly correlate with
human toxicity [104]. Species-specific differences exist in the microarchitecture of
mammalian brains, and rodents, for example, are predictive of human neurotoxicity in only
half the cases [9]. In addition, a substantial number of drug candidates have failed in
clinical trials even after successful animal studies. Therefore, various alternatives have
been pursued, including embryonic stem cells [105]–[107], neural stem/progenitor cells
(NSCs) [28], [108], [109], primary neuronal cells [97], [110], [111], and immortalized
neuronal cell lines [96], [112], [113] to reduce the use of animal models and provide
predictive developmental neurotoxicity. The focus of these alternatives is the development
of in vitro assay platforms for mechanism-based, target-specific endpoints to evaluate the
human health risk of various chemicals and environmental toxicants [8], [16], [61].
NSCs have been identified in several regions of the human brain in all stages of
developmental [58], and are capable of self-renewal and differentiation into neurons,
astrocytes, and oligodendrocytes. NSC proliferation, differentiation and migration are
crucial in human brain development; disturbance of which has been linked to
neurodevelopmental disorders [8], [61]. Therefore, development of an in vitro assay system
for assessing self-renewal and differentiation of NSCs is essential not only to identify
compounds that can cause neurodevelopmental disorders, but also to restrict the use of
those chemicals [3], [114], [115].
High-throughput assessment of NSC viability in an in vitro system, characterization
of its self-renewal and differentiation into specific lineages, and real-time monitoring with
quantification of the differentiation process are critical to implement in vitro cultures of
NSCs for applications in tissue engineering, disease modeling, and drug development. NSC
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differentiation is typically determined by monitoring changes in cell morphology and
assessing neural and glial lineage-specific biomarkers via often nonspecific
immunofluorescence assays. In addition, measuring the efficiency of NSC differentiation
under different culture conditions and as a function of time is tedious, inherently lowthroughput, and involves destruction of analyzed samples [116].
An in vitro model system for DNT testing should be capable of mimicking in vivo
human neurodevelopment. Assays carried out in two dimensional (2D) cell cultures are
limited in terms of cell-cell and cell-matrix interactions that are crucial for cell-signaling
and gap-junction connection formation, as well as for promoting proliferation and
differentiation [8]. To address these limitations, we have developed a miniaturized threedimensional (3D) NSC microarray platform for high-throughput assessment of cell
viability. This platform exploits a promoter-reporter assay system that generates stable
mCherry- and EGFP-expressing NSCs for high-throughput characterization of selfrenewal and differentiation. Using this high-throughput, high-content in vitro platform we
demonstrated high-throughput assessment of cell viability, self-renewal and lineagespecific differentiation of 3D NSC culture in spontaneous and directed differentiation
methods, thereby eliminating the need to use low-throughput immunofluorescence staining
to monitor the developmental stages of NSCs.
2.2. Materials and Method
2.2.1. Human NSC cultures
Human NSCs (ReNcell VM; EMD Millipore, Burlington, MA, USA) were
passaged in a complete ReNcell medium (ReNcell NSC maintenance medium, EMD
Millipore) supplemented with 20 ng/mL epidermal growth factor (EGF, EMD Millipore),
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20 ng/mL basic fibroblast growth factor (bFGF, EMD Millipore), and 1% (v/v)
penicillin/streptomycin (Thermo Fisher, Waltham, MA, USA), on laminin-coated, tissue
culture-treated, T-75 flasks in a humidified 5% CO2 incubator at 37 °C (Heracell 150i,
Thermo Fisher). The complete medium was replaced every two days with a freshly
prepared complete medium until the cells reached 90% confluency, after which they were
detached with accutase (EMD Millipore), suspended in ReNcell NSC maintenance
medium, and centrifuged. The resulting cell pellets were resuspended in the complete
medium, cell concentration determined, and 1.5  106 cells were seeded on freshly prepared
laminin-coated T-75 flasks.
2.2.2. Preparation of 3D-cultured ReNcell microarrays
All chemicals and reagents were from Sigma-Aldrich (St. Louis, MO, USA), unless
specified otherwise. For 3D microarray culture of ReNcell VM, micropillar chips (Medical
& Bio Device (MBD) Korea, Suwon, Republic of Korea) were coated with 0.01% (w/v)
poly(maleic anhydride alt-1-octadecene) (PMA-OD) and dried. A mixture of poly-L-lysine
(PLL) and barium chloride (BaCl2) was prepared at a final concentration of 0.0033% (w/v)
PLL and 16.66 mM BaCl2 in sterile deionized water and printed on top of the PMA-OD
coated micropillar chips at a volume of 60 nL, with an S+ Microarrayer (Advanced
Technology Inc. (ATI), Incheon, Republic of Korea) and dried. In parallel, a mixture of
PLL and CaCl2 was prepared in an analogous manner at a final concentration of 0.0033%
(w/v) PLL and 25 mM CaCl2 in sterile deionized water and printed on top of the PMA-OD
coated micropillar chips. The complete medium was printed into microwell chips (MBD
Korea) at a volume of 950 nL and stored in a humidified chamber for later use.
ReNcells were encapsulated in either alginate alone or in a mixture of alginate and
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growth factor reduced (GFR) Matrigel® (Corning, Corning, NY, USA). For the former,
ReNcell suspension was mixed with low-viscosity alginate, prepared from sodium alginate
powder reconstituted in sterile deionized water, to achieve a final cell concentration of
6106 cells/mL in 0.75% (w/v) alginate. Similarly, for encapsulation in a mixture of
alginate and GFR Matrigel, cell suspension was mixed with alginate and GFR Matrigel to
achieve a final cell concentration of 6106 cells/mL in a mixture of 0.75% (w/v) alginate
and 1 mg/mL GFR Matrigel and stored on ice until printing. The cell-hydrogel mixtures
were then printed on top of dried PLL/BaCl2 or PLL/CaCl2 layers (Figure 2.1), while
maintaining the slide deck (loaded with the micropillar chips) at 7 °C. After incubating the
chips on the slide deck for 2 mins for gelation, the micropillar chips with cell spots were
sandwiched with the microwell chips containing 950 nL of the complete medium. The
sandwiched micropillar and microwell chips were then stored in a humidified petri dish
and incubated at 37 °C in the 5% CO2 incubator.

24

Figure 2.1. Schematic diagram of 3D NSC microarray culture. (A) ReNcell VM in a
mixture of alginate and GFR Matrigel was printed on the functionalized micropillar chips,
and the complete ReNcell VM medium at a volume of 950 nL was printed into the
microwell chips. After hydrogel gelation, the micropillar chip with ReNcell VM spots was
sandwiched with the microwell chip containing the complete medium for 3D cell culture.
(B) Picture of the injection-molded micropillar and the microwell chips (25 mm x 75 mm)
used in this study is shown with respect to microscopic glass slide.
2.2.3. Cell viability assay
Viability and spheroid formation of ReNcell in 3D microarray culture were assessed
using Live/Dead® viability/cytotoxicity kit for mammalian cells (ThermoFisher). Briefly,
3D-cultured ReNcells on the micropillar chips were separated from the microwell chips
and rinsed twice with a saline solution containing 140 mM NaCl and 20 mM CaCl 2. The
micropillar chips were then stained with 0.5 µM calcein AM and 1 µM ethidium
homodimer-1 at room temperature for an hour, rinsed twice with the saline solution, and
dried in the dark for at least 3 hours to ensure complete drying of the micropillar chips.
Dried micropillar chips were then scanned with S+ scanner (ATI), an automated
epifluorescence microscope developed for rapid image acquisition at 15 frames per second
(FPS). Green and red fluorescent cell images were obtained at 4X magnification with the
Olympus UPLFLN 4X (numerical aperture (NA) 0.13, f-number 26.5, and depth of field
(DOF) ~ 32.3 µm) (Olympus, Tokyo, Japan) and a green filter (XF404 from Omega
Optical) and a red filter (TxRed-4040C from Semrock). The images were batch-processed
using ImageJ (NIH) to extract fluorescence intensity from the entire cell spots on the
micropillar chips. The fluorescence intensities were plotted using SigmaPlot software ver.
12 (Systat Software Inc., San Jose, CA, USA).
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2.2.4. Construction of dual reporter lentiviral vectors for the reporter gene assay
To construct lentiviral vectors having a dual reporter system, the promoter regions
of the human GFAP gene (ref, PMID: 19457099) and the synapsin I gene (ref, PMID:
19318117) were amplified using phGFAP-fLuc (Addgene 40589) and pLV-hSyn-RFP
(Addgene 22909) plasmids, respectively. The MBP (chr18-:72859280-72857953) and
SOX2 promoters (chr3+:182911368-182912675) were amplified from the genomic DNA
of ReNcell VM. The PCR products of each promoter and EGFP gene were assembled into
pLV-mCherry (Addgene 36084) via in-fusion assembly of multiple fragments (ref, PMID:
17907578), resulting in constructing pLV-mCherry-hGFAP-EGFP, pLV-mCherry-hSynEGFP, pLV-mCherry-hMBP-EGFP, and pLV-mCherry-hSOX2-EGFP, respectively.
2.2.5. Preparation of recombinant lentiviruses
Recombinant lentiviruses were prepared using 2nd generation packaging systems,
which require a single packaging plasmid (psPAX2, Addgene 12260), an envelope plasmid
(pMD2.G, Addgene 12259), and our transfer vectors including pLV-mCherry-hGFAPEGFP, pLV-mCherry-hSyn-EGFP, pLV-mCherry-hMBP-EGFP, or pLV-mCherry-hSOX2EGFP. Briefly, HEK293T cells (ATCC® CRL-3216™, Manassas, VA, USA) were grown
in T25 flasks in DMEM supplemented with 10% (v/v) FBS and 1% (v/v)
penicillin/streptomycin until 50-60% confluence was achieved. Two viral packaging
plasmids (pVSV-G for envelope and psPAX2 for packaging) and one transfer plasmid
carrying a gene for each specific biomarker (pLV-mCherry-hSOX2-EGFP for self-renewal,
pLV-mCherry-hSyn-EGFP for neurons, pLV-mCherry-hGFAP-EGFP for astrocytes, and
pLV-mCherry-hMBP-EGFP for oligodendrocytes) were mixed and added to HEK293T
cells and incubated at 37 °C in the 5% CO2 incubator. After 24 hours, the supernatant was
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collected from T25 flasks and fresh DMEM was added to the cells. The supernatant was
collected again after 3 days, pooled with the supernatant collected at day 1 and stored at 80 °C until further use. The transfer plasmid contains dual promoters (monomer cherry
protein, mCherry and enhanced green fluorescent protein, EGFP), which enables ReNcell
transduced with the lentiviruses to express mCherry under the control of CMV promoter,
while EGFP is expressed only when the NSC-specific biomarkers are turned on. These
recombinant viruses can be used to monitor self-renewal and differentiation of 3D-cultured
ReNcell in high throughput on the micropillar/microwell chip platform.
2.2.6. Characterization of ReNcells cultured in 2D
ReNcells were seeded on laminin-coated tissue culture-treated T25 flasks at 7105
cells/flask and incubated at 37 °C in the 5% CO2 incubator. Once the cells reached 50-60%
confluency, lentiviruses containing the reporter for SOX2, GFAP, synapsin1 or MBP were
diluted in the complete medium without antibiotics and added to their respective flasks for
infection. After overnight incubation, the lentivirus-containing medium was replaced with
a freshly prepared complete medium containing antibiotics. Lentivirus-infected cells were
grown until they reached 90% confluence, after which the cells were detached and
suspended in the complete medium. For 2D culture in 96-well plates, tissue-culture treated
flat-bottom 96-well plates were coated with laminin and lentivirus-infected cells were
seeded at 5,000 cells/well with 24 replicates per cell type. After two days of culture in the
complete medium, differentiation was induced by replacing the complete medium with a
differentiation medium (i.e., ReNcell maintenance medium without EGF and bFGF).
Differentiation was monitored over 21 days, with medium change every two days.
For 2D culture on the microarray chip platform, the micropillar chips were coated
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with 75 µg/mL poly-L-lysine (PLL) for 2 hours at 37 °C, and then with 40 µg/mL laminin
for 4 hours at 37 °C. Both lentivirus-infected and non-infected ReNcells in the complete
ReNcell medium was printed directly into the microwell chips at 6105 cells/mL and
sandwiched with the PLL and laminin-coated micropillar chips. The sandwiched chips with
the microwell chip on the top and the micropillar chip at the bottom were incubated
overnight at 37 °C in the 5% CO2 incubator, after which the spent medium was replaced
with a fresh medium. The viability of non-infected ReNcell VM after two weeks of culture
on the chip platform was assessed from live/dead staining with calcein AM and ethidium
homodimer-1. For the assessment of differentiation in lentivirus-infected ReNcells, growth
factors (EGF and bFGF) were removed after two days of incubation to induce NSC
differentiation. Images were obtained over a period of 10 days to monitor cell
differentiation with medium change every two days.
2.2.7. Immunofluorescence assays for comparison of ReNcell differentiation
Non-infected ReNcells were seeded on laminin-coated 96-well plates at 5,000
cells/well and incubated at 37 °C in the 5% CO2 incubator. The cells were grown for 10
days in the complete medium and in the differentiation medium (without EGF and bFGF),
with medium change every two days. The cells were rinsed briefly in 1 sterile PBS and
fixed with 4% paraformaldehyde for 10 minutes at 37 °C. After fixation, cells were washed
using 1 Tri-buffered saline (TBS) and blocked with 3% bovine serum albumin (BSA) in
1 TBS for 1 hour at 37 °C. The cells were then incubated overnight with their respective
primary antibodies for specific biomarkers; SOX2, MBP, GFAP, and synapsin1 (Santa Cruz
biotechnology, Dallas, TX, USA), which were diluted at 1:200 in the blocking solution.
After overnight incubation with primary antibodies, fluorophore-conjugated secondary
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antibodies – Alexa Fluor®488 anti-mouse and AlexaFluor® anti-goat Superclonal™
(Carlsbad, CA, Invitrogen) – were diluted at 1:200 in the blocking solution and added to
the cells for 1 hour at room temperature. This was followed by 4′,6-diamidino-2
phenylindole (DAPI; Sigma-Aldrich) staining for 10 minutes at room temperature and
image acquisition with an inverted fluorescence microscope (Axio Vert. A1, Zeiss,
Germany).
2.2.8. Characterization of ReNcells cultured in 3D
For 3D cell culture, cell suspensions of lentivirus-infected ReNcells were
encapsulated in a mixture of 0.75% (w/v) alginate and 1 mg/mL GFR Matrigel and printed
on top of PLL/CaCl2 coated micropillar chips. After gelation, the pillar chips were
sandwiched with the microwell chips containing 950 nL of the complete medium and
incubated at 37 °C in the 5% CO2 incubator. ReNcells were cultured on the
micropillar/microwell chip platform for four days, after which differentiation was induced
by replacing the complete medium in the microwell chips with the differentiation medium.
The cells were incubated in the differentiation medium for 7 days, with medium change
every two days, and ReNcell differentiation was captured using a Zeiss Axio Vert. A1
inverted fluorescence microscope.
2.2.9. Differentiation of lentivirus-infected ReNcells in 2D and 3D cultures with
compounds
To induce ReNcell differentiation in 2D and 3D cultures with additives, three
differentiation media were prepared in the complete medium by supplementing with 30
ng/mL triiodothyronine (T3) for oligodendrocytes [117]–[121], 1% N2 supplement for
29

astrocytes [122]–[125], and 0.5 mM 3-iso-butyl-1-methylxanthine (IBMX) for neurons
[126]–[128]. For differentiation in 2D culture on the chip, lentivirus-infected ReNcells in
the complete medium were printed in the microwell chips at 3106 cells/mL and
sandwiched with PLL and laminin-coated micropillar chips. The sandwiched chips were
incubated overnight at 37 °C in the 5% CO2 incubator after which the spent medium was
replaced with a fresh medium. After 4 days of incubation, monolayers of ReNcells on the
micropillar chip were exposed to the differentiation medium individually for 7 days, with
medium change every two days. For differentiation in 3D culture on the chip, lentivirusinfected ReNcells were encapsulated in a mixture of 0.75% (w/v) alginate and 1 mg/mL
GFR Matrigel and printed on PLL/CaCl2 coated micropillar chips. After gelation, the
micropillar chips were sandwiched with the microwell chips containing the complete
medium and incubated at 37 °C in the 5% CO2 incubator. The cells were incubated for 4
days in the complete medium, with medium change every two days before inducing
differentiation. Images of ReNcells in 2D and 3D cultures were obtained at two time-points
– 4 days before and 7 days after differentiation with the S+ scanner.
2.2.10. Statistical analysis
All the values were expressed as mean ± SD. For each test condition, n = 126
biological replicates per pillar chip per experiment were studied, and three individual
experiments were performed. Statistical analysis was performed with GraphPad Prism 5
(La Jolla, CA) and plotted in SigmaPlot 12 (San Jose, CA). For comparison between
various culture conditions, statistical significance (p < 0.01) between various culture
conditions was measured using a Student’s t-test.
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2.3. Results
2.3.1. Optimization of 3D ReNcell cultures on the micropillar/microwell chip platform
ReNcell VM was chosen due to its ability to self-renew and differentiate into
neurons and glial cells, and for its commercial availability as a human dopaminergic
neuroprogenitor cell line. These attributes make ReNcell a useful NSC model, although the
v-myc oncogene immortalization by retroviral transduction may impact neural cell
differentiation marker expression [129], [130]. Live/dead staining with calcein AM and
ethidium homodimer-1 was performed to assess ReNcell viability and spheroid formation
on the micropillar chips. The use of alginate hydrogel alone for 3D ReNcell cultures has
previously been shown to induce lag-phase of growth [26]. ReNcells encapsulated in
0.75 % (w/v) alginate with 16.66 mM BaCl2 as a crosslinker starting from day 1 of
incubation showed a time-dependent decrease in cell viability indicating some degree of
cytotoxicity (Figure 2.2A). On the other hand, the use of relatively nontoxic CaCl2 when
compared to BaCl2 as a crosslinker resulted in significantly improved cell viability and
increased 3D spheroid formation of ReNcells in alginate (Figure 2.2A). However, there
was still an initial lag phase of cell growth in alginate-alone conditions even with CaCl2
(Figure 2.2B). This problem was diminished by using a mixture of alginate and GFR
Matrigel. Combining GFR Matrigel with alginate significantly increased cell viability, cell
growth, and 3D spheroid formation over time on the micropillar chip, compared to the
alginate-alone conditions. Since alginate derived from brown seaweed is inert and not
degraded by cellular proteases, the mixture of alginate and GFR Matrigel provided strong
mechanical support and cell-extracellular matrix (cell-ECM) interactions for long-term
culture of ReNcell VM in 3D without any adverse effect on differentiation over two months
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(data not shown). Adding 1 mg/mL GFR Matrigel in 0.75% (w/v) alginate greatly enhanced
ReNcell VM viability on the micropillar chip over the 9-day cultures and supported
formation of ReNcell VM spheroids compared to that within 0.75% (w/v) alginate alone.
GFR Matrigel alone was not used as a matrix, as it was difficult to maintain sufficiently
low temperatures in the micro-solenoid valves and tubes, and thus prevent unwanted
gelation.
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Figure 2.2. Optimization of 3D ReNcell culture conditions on the microarray chip
platform. (A) Representative images of ReNcell VM encapsulated in 0.75% (w/v) alginate
alone with BaCl2, 0.75% (w/v) alginate alone with CaCl2, and 0.75% (w/v) alginate and 1
mg/mL GFR Matrigel® with CaCl2 on the micropillar chip. Cell viability was determined
over a period of 9 days by live/dead staining with calcein AM and ethidium homodimer-1.
The scale bar is 150 µm. Green dots from calcein AM staining represent live cells whereas
red dots from ethidium homodimer-1 staining represent dead cells. (B) Fluorescence
intensity extracted from ReNcell VM encapsulated in 0.75% (w/v) alginate alone with
BaCl2 (filled triangle), 0.75% (w/v) alginate alone with CaCl2 (filled circle), and 0.75%
(w/v) alginate and 1 mg/mL GFR Matrigel with CaCl2 (filled square). Statistically
significant fluorescence difference between alginate alone with CaCl2 and alginate-GFR
Matrigel with CaCl2 conditions is indicated by *** for P < 0.001. The difference between
the alginate-alone conditions with BaCl2 and CaCl2 was indicated by ### for P < 0.001.

2.3.2. Assessment of self-renewal and differentiation via the promoter-reporter assay
in 2D and 3D cultures
Recombinant lentiviruses were constructed carrying dual promoters, a mCherry gene for
measuring viral gene transduction efficiency and an EGFP gene for determining the
expression levels of four NSC-specific biomarkers, including SOX2 for self-renewal, MBP
for oligodendrocytes, GFAP for astrocytes, and synapsin1 for neurons (Figure 2.3).
Various multiplicities of infection (MOIs) were tested to identify the optimum
concentrations of each lentivirus by FACS analysis (data not shown). While removing
growth factors in the culture medium, real-time monitoring of self-renewal and
differentiation of ReNcell VM was performed with the promoter-reporter assay system in
96-well plates over a 21-day period (Figure 2.4). Increased expression of MBP, GFAP, and
synapsin1 was observed over this period with continued expression of SOX2.
Differentiation of non-infected ReNcell VM into neurons, astrocytes, and oligodendrocytes
was assessed in parallel, in laminin-coated 96-well plates over 10 days by using
immunofluorescence assays (Figure 2.5). Expression of all three lineages was observed
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over the 10 days period with increased expression of GFAP and synapsin1.

Figure 2.3. Construction of lentiviral vectors carrying promoter-reporter assay
system for high-throughput assessment of ReNcell VM differentiation. The CMV
promoter-driven mCherry gene is constitutively expressed in ReNcell VM, and EGFP gene
are expressed under control of cell-type specific promoters. Four NSC-specific biomarkers,
including SOX2, synapsin1, glial fibrillary acidic protein (GFAP), and myelin basic protein
(MBP), were used to evaluate self-renewal, neuron differentiation, astrocyte
differentiation, and oligodendrocyte differentiation, respectively. (Lentiviruses constructed
by Dr. Dordick’s group at RPI)

Figure 2.4. Promoter-reporter assay system for monitoring self-renewal and
differentaition of lentivirus-infected ReNcell monolayers in 96-well plates. Monolayers
of lentivirus-infected ReNcell VM were seeded in 96-well plates, and differentiation was
monitored after the removal of growth factors (EGF and bFGF) over a period of 21 days
through EGFP expression. The scale bar is 50 µm.
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Figure 2.5. Immunofluorescence assay for monitoring self-renewal and differentaition
of non-infected ReNcell monolayers in 96-well plates. Monolayers of ReNcell VM were
seeded in 96-well plates, and the expression levels of lineage-specific markers were
monitored after removal of growth factors (EGF and bFGF) over a period of 10 days
through immunofluorescence staining with anti-SOX2, anti-MBP, anti-GFAP, and antisynapsin1 antibodies. The scale bar is 50 µm. Blue dots indicate nucleus stained with
DAPI, green fluorescence indicates the expression of the respective biomarkers.

Self-renewal and differentiation characteristics of ReNcell VM were further
investigated in both 2D (Figure 2.6) and 3D (Figure 2.7) cultures on the
micropillar/microwell chip platform. mCherry expression indicates live ReNcells infected
with lentiviruses whereas EGFP expression indicates differentiation of ReNcells into
specific lineages. The cells infected with the SOX2 promoter-reporter lentivirus
demonstrated both EGFP and mCherry expression before differentiation, whereas the cells
infected with MBP, GFAP, and synapsin1 promoter-reporter lentiviruses showed only
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mCherry expression, indicating the self-renewal characteristics of ReNcell VM (Figures
2.6B and 2.7). EGFP expression in cells infected with MBP, GFAP, and synapsin1
promoter-reporter lentiviruses was observed only after differentiation. Out of the cell
population, 36% were differentiated into oligodendrocytes quantified from the EGFP
expression of MBP marker, 10% into astrocytes measured from GFAP marker expression,
and 7.5% into neurons measured from synapsin1 marker expression in the 3D culture of
ReNcell VM.

Figure 2.6. ReNcell monolayers cultured in 2D on the micropillar chip before and
after infection with lentiviruses. (A) 2D-cultured ReNcells on the micropillar chip were
monitored over time using brightfield and fluorescence microscopes. The cells were
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stained with calcein AM for determining viability after two weeks of culture on the
micropillar chip. The scale bar is 200 µm. (B) 2D-cultured ReNcells on the micropillar
chip were infected with lentiviruses and monitored over time for self-renewal and
differentiation. The red-colored cells indicate ReNcell VM infected with the lentiviruses.
The green-colored cells represent ReNcell VM differentiated into respective lineages. The
scale bar is 100 µm.

Figure 2.7. ReNcell VM cultured in 3D on the micropillar chip after infection with
lentiviruses for self-renewal and differentiation. Lentivirus-infected ReNcell VM
encapsulated in a mixture of 0.75% (w/v) alginate and 1 mg/mL GFR Matrigel was printed
on the micropillar chip. Differentiation was induced by removing the growth factors (EGF
and bFGF) in the growth medium. Images were obtained before and after differentiation (7
days) to determine the self-renewal and differentiation capability of ReNcell VM. The redcolored cells indicate the ReNcell VM infected with the lentiviruses, and the green-colored
cells indicate ReNcell VM differentiation into respective lineages. The scale bar is 200 µm.
We further evaluated the robustness and reproducibility of our promoter-reporter
assay by calculating the Z factor and the coefficient of variation (CV) [131], [132]. The
calculated Z factors for both self-renewal and differentiation assays were between 0.5
(SOX2) and 0.8 (MBP), indicating that the promoter-reporter assay is highly robust; a Z
factor between 0.5 and 1 is considered highly robust. Similarly, CV values were < 20%,
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showing the reproducibility of the promoter-reporter assay. The CV value for the selfrenewal assay was 17%, whereas it was 13% for MBP.
2.3.3. Compound-induced differentiation of 3D-cultured ReNcell microarrays with
the promoter-reporter assay
After establishing the promoter-reporter assay for monitoring self-renewal and
differentiation of ReNcell VM in the absence of growth factors, we assessed the
differentiation of ReNcell VM in 2D and 3D cultures with compounds well known to direct
NSCs into specific lineages. As a proof of concept, three compounds including T3, N2
supplement, and IBMX were used at a concentration that was known to direct NSCs into
oligodendrocytes, astrocytes, and neurons, respectively. The complete ReNcell medium
containing growth factors was supplemented with each of these compounds to prepare
three different growth medium forumulations, which were added to ReNcell VM cultures
after four days of pre-incubation with complete ReNcell medium. As a result, T3 induced
differentiation of ReNcells into oligodendrocytes, as evidenced by EGFP expression in
MBP lentivirus-infected cells (Figure 2.8). Similarly, the growth medium supplemented
with N2 supplement and IBMX induced differentiation of ReNcells into astrocytes and
neurons, respectively, which was evidenced by GFAP and synapsin1 expression,
respectively, in lentivirus-infected cells. As the outcomes were monitored only over a
period of 7 days after inducing diffferentiation, the level of EGFP expression was not
particularly high in individual cultures. Nonetheless, the assessment of self-renewal and
differentiation of ReNcell VM in both 2D and 3D cultures was observed without using cell
fixation and immunofluorescence staining, thus representing a major advantage of the
promoter-reporter assay system.
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Figure 2.8. ReNcell VM cultured in 2D and 3D on the micropillar chip after infection
with lentiviruses and exposed to compounds for inducing differentiation. Lentivirusinfected ReNcell VM were cultured in (A) 2D and (B) 3D using the complete medium
containing the growth factors supplemented with 30 ng/mL T3, 1% (w/v) N2, and 0.5 mM
IBMX for differentiation into oligodendrocytes, astrocytes, and neurons, respectively. The
scale bar is 50 µm. (Figure 2.8 generated by Dr. Kyeong-Nam Yu)
2.4. Discussion
The goal of this study was to develop an NSC-based in vitro 3D culture system that
enables high-throughput analysis of viability, growth, self-renewal, and differentiation of
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human NSCs in real-time, without the need for extensive post-culture sample processing.
3D on-chip NSC microarrays may serve as useful tools to model and analyze
neurodegenerative disorders in vitro. The features of microarray bioprinting such as
automated cell dispensing, miniaturized 3D cell culture, and high-throughput acquisition
and analysis of cell images make the micropillar/microwell chip platform of interest in
predictive modeling of DNT and high-throughput screening of compounds. ReNcell VM
was deemed a useful, albeit imperfect, cellular model, as the cells are capable of selfrenewal and differentiation into neurons and glial cells. This platform could be extended to
other NSC types such as ReNcell CX®, ENStem-A™, Gibco™ H9-derived NSCs, and
NSCs derived from human induced pluripotent stem cells (hiPSCs). Moreover, ReNcell
VM is a commercially available human neural progenitor cell line obtained from the
midbrain region of a 10-week human fetus and immortalized by retroviral transduction
with v-myc oncogene [77], [133]–[135].
Alginate was selected as a cell-encapsulation hydrogel as it is biologically inert
[136]. Cell-cell and cell-matrix interactions have been shown to alter cell morphology,
signaling mechanisms, and cell function [130], [137], [138]. GFR Matrigel was
supplemented with alginate to promote cell-ECM interactions. For cell-cell interactions,
which are important for NSC survival and proliferation, relatively high density of ReNcells
(6106 cells/mL) were printed on the micropillar chip, resulting in 360 cells/micropillar
within 60 nL of cell spots. The viability of ReNcell VM in alginate hydrogel was first
assessed with BaCl2 and CaCl2 as crosslinkers. Time-dependent decrease in ReNcell VM
viability in alginate gel crosslinked with BaCl2 was observed due to well-documented
cytotoxicity of BaCl2 against NSCs [26], [139]. Similar results were observed from human
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embryonic stem cells (hESCs) in alginate microcapsules crosslinked with 20 mM BaCl2,
where the viability decreased from 90% to 5% after 5 days of encapsulation [140]. Unlike
BaCl2, ReNcells encapsulated in alginate with CaCl2 maintained their viability after 5 days
of culture and spheroid formation. This lag-phase of ReNcell growth in alginate with CaCl2
has been previously reported [26], and we resolved this issue by supplementing GFR
Matrigel in alginate. In addition to cytotoxicity, the selection of divalent cations could
influence the permeability of nutrients as well as soluble factors such as growth factors and
compounds [139], [140].
The importance of cell-ECM interactions in maintaining self-renewal and in
guiding stem cell differentiation has been reported by several groups [141]–[144]. For
example, the intrinsic scaffold characteristics such as topology, elasticity, stiffness,
porosity, and pore size are known to play a key role in directing the differentiation of stem
cells into specific lineages [141], [143], [144]. Laminin is known to influence NSC
proliferation and differentiation [137], [142], and laminin-rich Matrigel could be highlyeffective in increasing NSC viability, proliferation, and differentiation [142]. Stem cells
typically remain in contact with basement membrane proteins during early developmental
stages in vivo. Matrigel, a basement membrane matrix rich in ECM components such as
laminin, entactin, collagen, and heparin sulfate proteoglycans [145], [146], is widely used
in 3D culturing of stem cells and neurons to provide cell-ECM interactions [147].
Therefore, addition of GFR Matrigel in alginate significantly enhanced cell viability and
spheroid formation of ReNcell VM in 3D culture on the micropillar/microwell chip
platform. Due to technical difficulties, such as the maintenance of low temperature in
micro-solenoid valves and tubes and reproducible cell printing, we supplemented 1 mg/mL
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GFR Matrigel in 075% alginate, which did not cause temperature-induced premature
gelation nor increased viscosity, while enhancing cell viability significantly.
NSCs are characterized by their ability of self-renewal and differentiation into
neural lineages. Lentiviral vectors are very effective for delivering transgenes into cultured
neural progenitor cells due to high tropism levels of neural tissues [148]. Therefore,
transgenic ReNcells were created with recombinant lentiviruses for high-throughput
analysis of self-renewal and differentiation in 2D and 3D cultures. Expression of NSCspecific markers demonstrated that removal of growth factors (EGF and bFGF) in ReNcell
cultures initiate the differentiation into glial and neuronal lineages. ReNcell VM expressed
EGFP for SOX2 before differentiation, which is the self-renewal marker of NSCs, whereas
there was no expression of EGFP for other differentiation markers, indicating the stemness
characteristics of ReNcell VM in the miniaturized 3D culture on the chip, which is in
accordance with previous studies [26], [130], [133]. NSCs maintain their pluripotency in
the presence of EGF and bFGF signaling (supplemented in the growth medium) [149], and
their removal encourages NSCs to differentiate into various lineages. In our study, removal
of growth factors induced EGFP expression for MBP, GFAP and synapsin1, indicating the
early stage differentiation of ReNcell VM into glial and neuronal lineages. MBP expression
was the highest with 36% differentiation compared to GFAP and synapsin1 at 10% and
7.5%, respectively, indicating increased differentiation into oligodendrocytes. Similar
results have been reported in microscale 3D NSC cultures in GFR Matrigel, where Olig2
expression for oligodendrocytes was significantly higher after differentiation compared to
3D cultures in collagen gel [40]. The ability of miniaturized 3D cell cultures to accumulate
soluble factors released from NSCs could be one reason for the increased expression of
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neural specific markers in NSC cultures after differentiation in Matrigel scaffolds [40].
Interestingly, we noted continued expression of SOX2 even after the induction of
differentiation. Similar to our observations, other groups have reported that SOX2 was
expressed in both 2D and 3D ReNcell VM cultures even after differentiation [130], or
SOX2 expression increased in v-myc immortalized cells [129], or SOX2 expression downregulated after NSC terminal differentiation as shown by expression of the III tubulin
marker [150]. These results suggest that pluripotency marker SOX2 continues to be
expressed until NSCs are terminally differentiated into specific lineages. Considering the
short period of induced differentiation (7-10 days) in our study, continued expression of
SOX2 could be justifiable.
Finally, we investigated the ability of ReNcell microarrays in 2D and 3D cultures
to perform compound-induced differentiation into oligodendrocytes, astrocytes, and
neurons. As a proof-of-concept, we selected one compound per lineage based on extensive
literature search, i.e., T3 for oligodendrocytes [119], [121], N2 for astrocytes [124], [125],
and IBMX for neurons [127], [128], which were chosen based on their role in cell survival
and differentiation to specific lineages, both in vitro and in vivo. For example, Jones et al.
demonstrated the effect of T3 on proliferation, survival, and differentiation of precursor
cells to oligodendrocytes in vitro [117]. Similarly, human neural progenitor cells
differentiated to oligodendrocytes after one week of treatment with 30 nM T3 [118].
Moreover, the role of T3 on differentiation, survival and proliferation of oligodendrocytes
has been validated in various in vivo studies with rat models [119], [121]. N2 supplement
has been widely used in NSC differentiation [122]–[124]. Shin and Vemuri used N2 to
optimally formulate the medium for differentiating human NSCs into astrocytes [122]. In
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a recent study, hiPSCs and hESCs were shown to differentiate into functionally mature
astrocytes in DMEM/F12 medium supplemented with N2 and B27 [124]. In addition,
hiPSC-derived neural progenitor cells in 3D cultures readily differentiated into astrocytes
after exposure to N2 in the growth medium [125]. In other studies, 0.5 mM IBMX was
shown to induce neuronal differentiation of human mesenchymal stem cells compared to
other compounds such as dibutyryl-cAMP and retinoic acid [126], and a significant
increase in the differentiation of rat mesenchymal stem cells into neurons was noted with
0.3 mM IBMX compared to other inducers such as 2-mercaptoethanol and tretinoin [127].
Collectively, T3, N2, and IBMX have been widely used for directed differentiation of NSCs
into oligodendrocytes, astrocytes, and neurons, which was demonstrated successfully using
lentivirus-infected ReNcells on the micropillar/microwell chip platform.
2.5. Conclusions
In this chapter, we successfully established miniaturized 3D ReNcell VM culture
in alginate-Matrigel matrices on the micropillar/microwell chip platform and demonstrated
high-throughput assessment of lineage-specific differentiation with lentivirus-infected
ReNcells by using the growth medium without growth factors as well as the complete
growth medium with differentiation inducers. The recombinant lentiviruses with dual
promoters – mCherry for constitutive expression to measure viral transduction efficiency
and EGFP for NSC-specific biomarkers – were highly effective in quantitatively assessing
ReNcell differentiation into neurons, astrocytes, and oligodendrocytes. The promoterreporter assay system developed herein with recombinant lentiviruses to monitor NSC
developmental stages is straightforward to use to calculate the efficiency of cell
differentiation and self-renewal by simply comparing green and red fluorescence
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intensities from ReNcell cultures on the chip, compared to time-consuming
immunofluorescence assays, which are known to give variable specificities and variable
responses. In conclusion, our system may be used to predict rapidly and accurately the
effects of a variety of compounds on NSC differentiation, survival, and proliferation, with
high reproducibility. 3D ReNcell microarrays also may be combined with high-content
imaging assays to detect critical changes in NSC morphology, cell function, molecular
actions on cell surface receptors, and mechanisms of toxicity, thereby ultimately enhancing
the predictability of DNT in vivo.
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CHAPTER III
ESTABLISHMENT OF ION CHANNEL AND ABC-TRANSPORTER ASSAYS
(MEMBRANE PROTEINS) IN 3D-CULTURED NSC MICROARRAYS FOR
HIGH-THROUGHPUT NEUROTOXICITY ASSESSMENT
3.1. Introduction
Membrane proteins such as ion channels and transporters are involved in cell-cell
signaling, transporting ions and molecules across the membrane, mediating the immune
system, and energy transduction [151]. Ion channels are a class of membrane proteins that
play a vital role in the development and function of human brains [152]–[155]. They
regulate several physiological processes in human brains including proliferation [156],
migration [157], and differentiation [152], and are involved in disease pathogenesis as well
[158], [159]. Nearly 13% of pharmaceutical drugs target ion channels as their primary
therapeutic targets due to their involvement in a wide range of physiological processes and
disease pathogenesis [160]–[165]. In addition, several ion channels with relevance to
specific diseases have been identified for drug discovery [163]. Therefore, identifying
potent and selective ion channel modulators will undoubtedly contribute towards reducing
the effect of neurodevelopmental disorders and neurological diseases.
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Despite the knowledge of ion channels as a major target for drug discovery, the
progress in this field has been limited due to the lack of availability of HTS platforms for
the assessment of ion channel activities. Most of ion channel studies still rely on labor
intensive patch-clamp electrophysiology assays. Although a new generation of automated
patch clamp systems have been developed to record multiple cells simultaneously, their
throughput is still limited for applications in HTS of pharmaceutical drugs and industrial
chemicals [164] [166]. Despite the sophisticated technologies, automated patch-clamp
technology possesses challenges in terms of reproducibility. The patch-clamp assays
further require a large number of cells, which is infeasible when it comes to screening
potential drug candidates in primary cells from patients. In addition, these patch-clamp
methods are expensive, requiring big capital investment and highly skilled personnel [163],
[164].
Likewise, influx and efflux transporters represent a major class of membrane
proteins that are located on the cell membrane through which they transport nutrients and
waste products, and assist in sensing environmental conditions [151][3, 4]. Among them,
ATP-binding cassette (ABC) transporters characterized by homologous ATP binding
transport various drugs and drug conjugates out of the cells via energy-dependent
mechanisms and play an important role in drug disposition in humans [167], [168]. Three
major drug-transporting ABC-transporters including MDR1, MRP1, and BCRP
demonstrate broad substrate specificities for a wide range of compounds such as
endogenous compounds, drugs, and metabolites [167]–[169]. Owing to the important role
of ABC transporters in absorption and disposition of drugs, pharmaceutical companies
have been investigating the interactions between drug candidates and ABC-transporters to
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determine the substrate/inhibitor relationship [170]. Several in vitro studies have shown
the effect of inhibitors and activators on the modulation of these efflux transporters. In vitro
transporter assays based on cellular models have been recognized as a low-cost and highthroughput alternative for in vivo animal studies [171]. One of the most common highthroughput cellular assays used for the assessment of transporter activity is the
accumulation assay where the accumulation/uptake of fluorescent dyes is measured in the
presence or absence of known transporter modulators. Increased fluorescence intensity due
to increased accumulation of fluorescent substrates is observed in the presence of
transporter inhibitors whereas decreased accumulation is observed in the presence of
activators or inducers [171], [172].
Cell-based assays utilizing bright fluorescent dyes have become a valuable tool to
rapidly screen and investigate the effect of potential modulators for ion channels as well as
transporters [163], [164], [173]. Several studies have been performed to identify ion
channel modulators and transporter inhibitors in various cell lines [173]. However, most of
these in vitro cell-based studies are performed using cell lines overexpressing ion channels
and transporters to amplify signal intensity, which often do not represent indigenous neural
stem cells (NSCs) that are important for the assessment of developmental neurotoxicity. In
addition, current ion channel and transporter assays have been performed on 2D
monolayers, which may limit predictivity of the assays [56]. Thus, 3D cell culture
platforms are necessary to investigate potential developmental neurotoxicity of drug
candidates and environmental toxicants using high-throughput assays for ion channels and
transporters. The overarching goal of this study is to establish high-throughput ion channel
and transporter assays on a 384-pillar plate with 3D-cultured ReNcell VM, an immortalized
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human neural stem cell line, which can be used for screening ion channel modulators and
transporter inhibitors. RNA sequencing data analysis of ReNcell VM is performed to
identify ion channels and transporters uniquely expressed in ReNcell VM. In addition,
fluorescence-based ion channel and transporter assays have been established in 3Dcultured ReNcell VM and validated with model compounds.
3.2. Materials and Methods
3.2.1. Analysis of RNA-sequencing (RNA-Seq) data
For RNA-Seq data analysis of ReNcell VM, raw sequencing files were obtained from the
Sequence Read Archive (SRA) with accession number GSE89623 and converted into
FASTQ files. Quality control (QC) of the RNA-Seq reads was performed using FastQC.
The mean quality score for each base pair was verified to be above 28, indicating good
quality base calls in the library. Reads in the FASTQ files were then processed and aligned
to the UCSC homo sapiens reference genome (build hg38) using Spliced Transcripts
Alignment to a Reference (STAR) Version 2.5.2b-0. The aligned BAM files were used to
find abundance of gene expression using Salmon. Abundance data was normalized using
edgeR to find count per million transcripts (CPM) for each gene variant, and the genes of
interest were extracted. Since RNA-Seq can provide alternatively spliced variant of each
gene, the splice variant with the highest abundance was selected. The expression data was
visualized using web-based data visualization tool called Clustergrammer (Figure 3.1).
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Figure 3.1. Workflow of the different steps carried out in RNA-Seq data analysis
pipeline. Raw data was obtained from SRA with accession number GSE89623 and
converted into FASTQ files. Quality control (QC) for the RNA-Seq reads was assessed
using FastQC. The reads in the FASTQ files were aligned to the human genome with
Spliced Transcripts Alignment to a Reference (STAR). Salmon was applied to assign reads
to genes, and visualization of gene clusters was implemented with web-based data
visualization tool called Clustergrammer (Data analysis performed by Rushabh Patel).

3.2.2. NSC culture in 2D
ReNcell VM (EMD Millipore, Burlington, MA, USA) was passaged in a complete NSC
medium (ReNcell NSC maintenance medium, EMD Millipore) supplemented with 20
ng/mL epidermal growth factor (EGF, EMD Millipore), 20 ng/mL basic fibroblast growth
factor (bFGF, EMD Millipore), and 1% (v/v) penicillin/streptomycin (P/S, Thermo Fisher,
Waltham, MA, USA) on laminin-coated, tissue culture-treated, T-75 flasks in a humidified
5% CO2 incubator at 37°C. The complete NSC medium was replaced every 2 d with a
freshly-prepared complete medium until the cells reached 90% confluency, after which
they were detached with Accutase™ (EMD Millipore), suspended in ReNcell NSC
maintenance medium, and centrifuged at 300 g for 4 min. The resulting cell pellet was
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resuspended in the complete NSC medium to determine cell density using a Moxi cell
counter (ORFLO Technologies, MXZ001), and then 1.5  106 cells were seeded on freshly
prepared laminin-coated T-75 flasks.
3.2.3. NSC culture in 3D on a 384-pillar plate
For 3D culture of ReNcell VM, 384-pillar plates (MBD, Suwon, South Korea) were coated
with 0.01% (w/v) poly(maleic anhydride alt-1-octadecene) (PMA-OD) and dried for atleast 4-6 h at room temperature. A mixture of 0.0033% (w/v) poly-L-lysine (PLL) and 25
mM calcium chloride (CaCl2) was prepared in sterile deionized water and printed on top
of the PMA-OD-coated 384-pillar plates at a volume of 2 µL with a microarray spotter (S+
Microarrayer, Samsung Electro Mechanics Co. or SEMCO, Suwon, South Korea). NSC
medium plates were prepared by dispensing the complete NSC medium into 384-well
plates (Corning) at a volume of 50 µL per 384-well and incubated in the 5% CO2 incubator
at 37°C for later use. For 3D NSC culture on the 384-pillar plate, the suspension of ReNcell
VM was mixed with 3% (w/v) low-viscosity alginate (Sigma-Aldrich) and 15 mg/mL
growth factor reduced (GFR) Geltrex® (ThermoFisher) to achieve a final cell concentration
of 2106 cells/mL in 0.75% (w/v) alginate and 2.5 mg/mL Geltrex and stored on ice until
printing. The suspension of ReNcell VM in the alginate-Geltrex mixture was then printed
on top of dried PLL/CaCl2 spots at a volume of 2 µL (4,000 cells per 384-pillar) while
maintaining the slide deck at 7°C to prevent water evaporation during printing (Figure
3.2). The 384-pillar plates were left on the chilling slide deck for 4 min for gelation and
then sandwiched with the 384-well plates containing 50 µL of the complete NSC medium
per 384-well. The sandwiched 384-pillar/well plates were incubated in the 5% CO2
incubator at 37°C.
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Figure 3.2. Schematics and pictures of the 384-pillar plate with NSCs encapsulated in
hydrogel spots. ReNcell VM was suspended in a mixture of 0.75% (w/v) alginate and 2.5
mg/mL GFR Geltrex at a final density of 2106 cells/mL and printed at a volume of 2 µL
on the 384-pillar plate coated with PMA-OD and PLL+CaCl2 layers.

3.2.4. Establishment of ion channel assays in 2D- and 3D-cultured ReNcell VM
Potassium ion channel assay
FluxOR™ potassium ion channel assay kit (ThermoFisher) was used to establish highthroughput potassium ion channel assays in 2D- and 3D-cultured ReNcell VM. For the 2D
cell assay, ReNcell VM suspension at 10,000 cells/well was seeded in a 96-well plate and
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incubated in the 5% CO2 incubator at 37°C for 48 h. All the buffer solutions, including the
loading buffer containing the FluxOR™ reagent, the assay buffer, and the stimulus buffer
containing thallium sulfate, were prepared according to the manufacturer’s protocol.
Powerload™ concentrate and water-soluble probenecid were used as directed by the kit
protocol to enhance the dye solubility and retention. Stock solutions of model compounds,
such as XE-991 and fluoxetine (both from Sigma-Aldrich), were prepared in DMSO at a
concentration of 25 mM and 50 mM, respectively. The cells in the 96-well plate were
treated with the loading buffer for 60 min at room temperature, after which the loading
buffer was removed and replaced with the assay buffer. Baseline reading was obtained with
a microtiter plate reader (Synergy H1, BioTek) at 475 nm excitation and 530 nm emission,
and then the assay buffer was removed. XE-991 and fluoxetine were diluted in the stimulus
buffer at six different concentrations including a stimulus buffer only control and added to
the 96-well plate with the cells, which was immediately followed by kinetic reading of the
fluorescent intensity in the microtiter plate reader.
For the 3D cell assay, ReNcell VM encapsulated in 0.75% (w/v) alginate and 2.5
mg/mL GFR Geltrex on the 384-pillar plate was incubated in the complete NSC medium
for 4 d prior to performing the FluxOR™ assay. The loading buffer was dispensed into a
384-well plate at 50 µL/well, and 3D-cultured ReNcell VM on the 384-pillar plate was
incubated with the loading buffer in the 384-well plate for 60 min at room temperature.
After incubation with the loading buffer, the cells on the 384-pillar plate were washed once
with a dye-free assay buffer in a 384-well plate before treating with XE-991 and fluoxetine
in the stimulus buffer. XE-991 and fluoxetine were diluted in the stimulus buffer at six
dosages including the control and added to a 384-well plate. The cells were incubated with
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the stimulus buffer contatining the two potassium ion channel blockers, immediately
followed by kinetic reading of thallium-sensitive fluorescence intensity from the microtiter
plate reader.
Store-operated calcium ion channel assay
Fluo-4 Direct calcium channel assay (ThermoFisher) was used to establish high-throughput
calcium channel assays in ReNcell VM culture. The stock solution of 2X Fluo-4 Direct
calcium reagent was prepared in 10 mL of Fluo-4 Direct calcium assay buffer according to
the manufacturer’s protocol. The stock solution of 2-aminoethyldiphenyl borinate (2-APB)
(Sigma-Aldrich) was prepared in DMSO at a concentration of 100 mM. Fluo-4 Direct
reagent was diluted in the NSC medium at 1:1 ratio to obtain the final concentration of the
reagent with 5 mM of Probenecid in the final solution. Six concentrations of 2-APB were
prepared in Fluo-4 Direct assay buffer. For the 2D cell assay, ReNcell VM suspension was
seeded at 10,000 cells/well in a 96-well plate and incubated with the complete NSC
medium in the 5% CO2 incubator at 37°C for 48 h prior to the assay. On the day of the
assay, the cells in the 96-well plate were loaded with Fluo-4 Direct reagent and incubated
for 60 min at room temperature, after which the cells were treated with six dosages of 2APB. Kinetic reading of fluorescence intensity was performed over a period of 1 h with 10
min interval with the microtiter plate reader at 494 nm excitation and 516 nm emission.
For the 3D cell assay, ReNcell VM encapsulated in 0.75% (w/v) alginate and 2.5
mg/mL GFR Geltrex on the 384-pillar plate was incubated in the complete NSC medium
in a 384-well plate for 4 d prior to performing the Fluo-4 Direct assay. The stock solution
of Fluo-4 Direct reagent was diluted in the NSC medium to obtain the final concentration
and added to a 384-well plate at a volume of 50 µL/well. The cells on the 384-pillar plate
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were incubated with the reagent in a 384-well plate for 60 min at room temperature, after
which the cells were exposed to six dosages of 2-APB including a no compound control.
The changes in fluorescence intensity were monitored with the microtiter plate reader over
time.
Measuring ion channel activities in ReNcell VM
The changes in fluorescence intensity for both the FluxOR potassium ion channel assay
and the Fluo-4 Direct calcium ion channel assay were obtained from the microtiter plate
reader. The intensity reading was normalized with control conditions (i.e., stimulus buffer
without XE-991 and fluoxetine for the potassium ion channel assay and the Fluo-4 Direct
assay buffer without 2-APB for the calcium ion channel assay) and dose response curves
were obtained using GraphPad Prism (GraphPad Software, San Diego, CA).
3.2.5. Establishment of transporter assays in 2D- and 3D-cultured ReNcell VM
Identification and evaluation of fluorescent substrates and transporter inhibitors
Inhibitors specific to

three major ABC-transporters including verapamil for

ABCB1/MDR1, MK-571 and probenecid for ABCCs/MRPs, and novobiocin for
ABCG2/BCRP (all from Sigma-Aldrich) were selected from literature search. Optimum
concentrations of these inhibitors were determined based on their effect on viability of 2Dcultured ReNcell VM. Briefly, ReNcell VM was seeded in a laminin-coated, 96-well plate
at 10,000 cells/well and incubated in the 5% CO2 incubator at 37°C for 48 h. After 48 h of
incubation, the cells were exposed to six dosages of the ABC transporter inhibitors such
as verapamil (0.8 - 200 µM), MK-571 (1.6 - 400 µM), probenecid (0.8 - 200 µM), and
novobiocin (1.6 - 400 µM) for 2 h, stained with calcein AM at 0.25 µM for 30 min, and
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then scanned with an automated fluorescent microscope (S+ scanner, SEMCO) to assess
cell viability. The fluorescent cell images were obtained with a green filter (XF404 from
Omega Optical), a red filter (TxRed-4040C from Semrock), and a blue filter (DAPI-5060C
from Semrock) at 4 magnification with the Olympus UPLFLN 4× (numerical aperture
(NA) 0.13, f-number 26.5, and depth of field (DOF) ~ 32.3 μm) (Olympus, Tokyo, Japan).
Cell images obtained from the 384-pillar plates were batch-processed using ImageJ (NIH)
to extract fluorescence intensity from the entire cell spots and were analyzed using
SigmaPlot software ver. 12 (Systat Software Inc., San Jose, CA, USA).
Calcein AM and Hoechst 33342 were evaluated for their application as fluorescent
substrates of the three ABC-transporters. Briefly, ReNcell VM seeded in two 96-well plates
at 10,000 cells/well and cultured in the 5% CO2 incubator at 37°C for 48 h was exposed to
six dosages of the ABC-transporter inhibitors, including verapamil (0.8 - 200 µM) for
MDR1, MK-571 (0.4 - 100 µM) and probenecid (0.8 - 200 µM) for MRP1, and novobiocin
(1.6 - 400 µM) for BCRP, all prepared in two complete NSC media containing either 0.25
µM calcein AM or 10 µM Hoechst 33342. After removing old NSC media, inhibitor
solutions containing either calcein AM or Hoechst 33342 were added to the 96-well plates
with the cells. The cells were incubated at 37°C for 45 min, after which the inhibitor
solutions were removed, and the 96-well plates were rinsed with cold D-PBS before
fluorescence reading. The changes in fluorescence intensity in the 96-well plates were
determined by the microtiter plate reader at 490 nm excitation and 520 nm emission for
green fluorescence from calcein AM and at 350 nm excitation and 461 nm emission for
blue fluorescence from Hoechst 33342.
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Establishing high-throughput ABC-transporter assays in 3D-cultured ReNcell VM
To establish high-throughput ABC transporter assays on the 384-pillar plate with 3Dcultured ReNcell VM, Hoechst 33342 was used to measure activities of MDR1, MRP1,
and BCRP in the presence and absence of specific inhibitors of the three transporters,
including verapamil for MDR1, probenecid for MRP1, and novobiocin for BCRP. Briefly,
ReNcell VM encapsulated in 0.75% (w/v) alginate and 2.5 mg/mL GFR Geltrex on the
384-pillar plate was sandwiched with the complete NSC medium in a 384-well plate and
cultured in the 5% CO2 incubator at 37°C for 4 d to ensure 3D spheroid formation. Varying
concentrations of verapamil (0.8 - 200 µM), probenecid (0.8 - 200 µM), and novobiocin
(1.6 - 400 µM) were prepared in the complete NSC medium containing 10 µM Hoechst
33342. 3D-cultured ReNcell VM on the 384-pillar plate was exposed to the inhibitors in
the 384-well plate for 60 min, after which the inhibitors were removed, and the 384-pillar
plate was rinsed with a cold saline solution. The changes in blue fluorescence intensity was
determined by the microtiter plate reader and fluorescent cell images were acquired by the
S+ scanner.
Assessment of ABC transporter activities in 3D-cultured ReNcell VM
Hoechst 33342 was used to measure the activity of the ABC transporters by
blocking MDR1, MRP1, and BCRP in 3D-cultured ReNcell VM using verapamil,
probenecid, and novobiocin. Fluorescence intensity was obtained to determine the
transporter activity factor (TAF) of the ABC transporters using the following equation:
TAF = [(Fn – Fcntrl) / Fn]  100
where, Fn is the fluorescence intensity from inhibitor-treated ReNcell VM and Fcntrl is the
fluorescence intensity from the untreated control sample.
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3.3. Results
3.3.1. Expression of ion channels in ReNcell VM
Since RNA-Seq can provide alternatively spliced variant of each gene, the splice variant
with the highest abundance was selected. From RNA-Seq analysis, we found that there are
low expression levels of all voltage-gated sodium ion channels, voltage-gated calcium ion
channels, and major chloride ion channels in undifferentiated ReNcell VM. Interestingly,
voltage-gated potassium channels including KCNQ2 (Kv 7.2) and KCND3 (Kv 4.3) were
expressed at relatively high levels as compared to other voltage-gated and non-voltage
gated potassium ion channels (Figure 3.3). In addition, store-operated calcium channels
(SOCCs) showed higher expression levels as compared to other types of calcium ion
channels (Figure 3.4). Thus, we focused on these potassium and calcium ion channels in
the follow-up experiments.
Voltage-gated
Na+ channels

Voltage-gated
K+ channels

Resting K+
channels

Inwardly rectifying
K+ channels

Voltage-gated K+ channels

Voltage-gated
Ca+ channels

ReNcell VM 1
ReNcell VM 2

Figure 3.3. Gene expression level of major ion channels in ReNcell VM visualized in
Clustergrammer after processing RNA-Seq data obtained from the RNA-Seq
workflow. Only few voltage-gated potassium ion channels are well expressed in ReNcell
VM as compared to other potassium ion channels, sodium ion channels, and calcium ion
channels.
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Figure 3.4. Gene expression level of voltage-gated calcium channels (VGCCs) and
store-operated calcium channels (SOCCs) in ReNcell VM visualized in
Clustergrammer. Only SOCCs are well expressed in ReNcell VM in comparison to
VGCCs.
3.3.2. Viability of 3D-cultured NSC on 384-pillar plate
The ability of self-renewal and differentiation into neurons and glial cells makes ReNcell
VM human neural progenitor cell line a suitable NSC model for DNT studies (Breier et al.
2010; Kim et al. 2015). ReNcell VM viability and spheroid formation in 3D culture on the
384-pillar plate were assessed over time (days 2, 4, 6, and 14) with calcein AM and
ethidium homodimer-1 staining. In chapter 2, we demonstrated improved viability and
spheroid formation of ReNcell VM in the mixture of 0.75% (w/v) alginate and 1 mg/mL
GFR Matrigel on a micropillar chip with 60 nL of cell spots. However, the micropillar chip
was small (25 mm  75 mm) for easy maneuverability and incompatible with HTS
instruments used widely. Thus, we have established 3D-cultures of ReNcell VM on a 384pillar plate, which contains 16  24 pillar arrays (i.e., 384 pillars) and compatible with
conventional 384-well plates and HTS instruments. This is the first demonstration of HCI
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assays on 3D-cultured ReNcell VM on the 384-pillar plate for the assessment of DNT. GFR
Matrigel was replaced with GFR Geltrex because Geltrex is free from lactate
dehydrogenase-elevating virus (LDEV) and has less lot-to-lot variation in protein
composition although both Geltrex and Matrigel are purified from basement membrane
extract of Engelbreth-Holm-Swarm mouse sarcoma cells and have similar compositions.
High viability of ReNcell VM in a mixture of 0.75% (w/v) alginate and 2.5 mg/mL GFR
Geltrex was maintained over a period of two weeks as evidenced by the increased size of
spheroids and the increased fluorescence intensity from the ReNcell VM images at days 2,
4, 6, and 14 (Figure 3.5). The green-colored dots represent live cells stained with calcein
AM. The 3D-cultured ReNcell VM on the 384-pillar plate was maintained further over a
period of two months to establish long-term cell culture on the 384-pillar plate with calcein
AM staining at day 14, and H&E staining after two months, to monitor changes in cell
viability and morphology (Figure 3.6). ReNcell VM formed large spheroids of nearly 400
µm in average diameter and maintained high viability as indicated by the green color in
Figure 3.5A. In addition, H&E staining after two months revealed compact hydrogel spots
filled completely with 3D spheroids as seen in Figure 3.6.
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Figure 3.5. Viability and growth of 3D-cultured ReNcell VM on the 384-pillar plate.
(A) ReNcell VM cells mixed with 0.75% (w/v) alginate and 2.5 mg/mL GFR Geltrex,
printed on the 384-pillar plate, incubated for 14 days, and stained with Live/Dead®
viability/cytotoxicity kit at day 2, 4, 6, and 14. Green dots represent live cells stained with
0.25 µM calcein AM. Spheroid formation can be observed from day 6. The scale bar is 400
µm. (B) Changes in green fluorescence intensity in 3D-cultures of ReNcell VM over 2
weeks.
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(A)

200 µm

(B)

20 µm

Figure 3.6. Long-term (2-months) 3D culture of ReNcell VM on the 384-pillar plate.
(A) Cross-sectional image of a single ReNcell spot (2 μL) after two months of incubation
on the 384-pillar plate. The cell spot containing ReNcell spheroids was fixed with 4%
paraformaldehyde and embedded in the paraffin cassette to make slices. To observe
ReNcell spheroids, the cross-sectioned slice on the glass slide was stained with
hematoxylin and eosin. Scale bar: 200 µm. (B) The blown-up image of the ReNcell
spheroids. The red arrows indicate nuclei stained with hematoxylin. The entire hydrogel
spot was packed with ReNcell spheroids, which remained viable and exhibited normal 3D
morphology. Scale bar: 20 µm.

3.3.3. Ion channel activities in 2D- and 3D-cultured ReNcell VM
ReNcell VM-based potassium channel assays were established in 2D and 3D culture using
FluxOR™ potassium ion channel assay kit containing a membrane-permeable FluxOR™
reagent that is transformed into a fluorogenic thallium-sensitive indicator inside the cells.
When thallium ions are added to the cells by opening potassium ion channels with a
stimulus buffer, the thallium-sensitive dye binds to thallium ions and generates a green
fluorescent signal. To measure the activity of the specific voltage-gated potassium channels
highly expressed in ReNcell VM, we selected inhibitors specifically binding to each

62

channel (i.e., XE-991 for Kv 7.2 channel and fluoxetine for Kv 4.3 channel). Six dosages
of XE-991 (0.4 - 100 µM) and fluoxetine (0.4 - 100 µM), including a no compound control,
were prepared in the stimulus buffer to observe inhibition of specific potassium ion channel
activity. Nearly 30% inhibition of Kv 7.2 channel and 20% inhibition of Kv 4.3 channel
were observed in both 2D- and 3D-cultured ReNcell VM at the highest dosage of XE-991
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and fluoxetine, respectively (Figure 3.7).
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Figure 3.7. Potassium channel activity in 2D- and 3D-cultured ReNcell VM. For the
2D cell assay, ReNcell VM was seeded in the 96-well plate with 10,000 cells/well and
incubated for 2 d before performing the assay (n=6). ReNcell VM was encapsulated in a
mixture of 0.75% (w/v) alginate and 2.5 mg/mL GFR Matrigel and cultured for 4 d for 3D
cell culture before performing the potassium ion channel assay (n=12). On the day of the
assay, the cells were loaded with thallium-sensitive FluxOR reagent and treated with XE991 (Kv 7.2 channel blocker) and fluoxetine (Kv 4.3 channel blocker) along with thallium
stimulus to observe the activity of the potassium ion channels.
From the RNA-Seq analysis, we also found that voltage-gated calcium ion channels are
not expressed in ReNcell VM. Therefore, we focused on non-voltage gated calcium ion
channels such as SOCCs that were shown to be expressed in ReNcell VM (Figure 3.4) and
selected 2-APB, which is a widely used SOCC modulator. To measure the SOCC activity
in 3D-cultured ReNcell VM, a cell-based calcium channel assay was established using
Fluo-4 Direct calcium ion channel assay kit. The kit contains a membrane-permeable Fluo63

4 Direct reagent, which is hydrolyzed by esterases inside the cells into a calcium-sensitive
fluorescence reagent. When calcium ions enter inside the cells or are released from
endoplasmic reticulum (ER) due to SOCC activity, green fluorescence is observed. The
cells were loaded with Fluo-4 Direct reagent for 1 h, after which the cells were exposed to
six dosages (0.4 – 100 µM) of 2-APB including a no compound control, and the
fluorescence intensity reading was obtained. The highest activation of SOCC was observed
at 6.25 µM from both 2D- and 3D-cultured ReNcell VM (Figure 3.8). Inhibition of the
SOCC activity was observed beyond that concentration (i.e., 25 - 100 µM), which is
correlated well with literature [174], [175].
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Figure 3.8. Store-operated calcium channel (SOCC) activity in 2D- and 3D-cultured
ReNcell VM. For the 2D cell assay, ReNcell VM was seeded in the 96-well plate with
10,000 cells/well and incubated for 2 d before performing the assay (n=6). For the 3D cell
assay, ReNcell VM was encapsulated in a mixture of 0.75% (w/v) alginate and 2.5 mg/mL
GFR Matrigel and cultured for 4 d before performing the calcium channel assay (n=12).
Both cells were loaded with Fluo-4 Direct reagent and treated with 2-APB (SOCC
modulator) to observe the changes in the activity of calcium channels over time. The 2APB exhibited biphasic behavior by activating SOCCs at lower concentrations (1.56 - 6.25
µM) and inhibiting the channels at higher concentrations (25 -100 µM), which is well
correlated with the mechanism of 2-APB action.
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3.3.4. ABC transporter activities in ReNcell VM
The concentrations of transporter inhibitors which are nontoxic to ReNcell VM were
selected to accurately measure transporter activity. Verapamil at 200 µM and MK-571
above (Figure 3.9). Calcein AM has been widely known as a fluorescent substrate for
MDR and MRP transporters, but the inhibition of MDR1 and MRP1 transporters in
ReNcell VM with verapamil and probenecid, did not lead to increase in green fluorescence.
On the other hand, Hoechst 33342 widely used as a fluorescence substrate for BCRP and
MDR1 transporters, was found to be a useful substrate for MRP1 transporter as well as
indicated by the increase in fluorescence with probenecid (Figure 3.10). We further found
that MK-571 did not selectively inhibit the MRP transporter for both fluorescent substrates,
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Figure 3.9. Basal toxicity of ReNcell VM with the transporter inhibitors. ReNcell VM
seeded in the 96-well plate was treated with various concentrations of verapamil, MK-571,
probenecid, and novobiocin and stained with 0.25 µM calcein AM to determine the noncytotoxic ranges of the inhibitors for accurate assessment of transporter activity (n = 6).
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Figure 3.10. Hoechst 33342 used to determine MRP1 transporter inhibition with
probenecid. ReNcell VM seeded in the 96-well plate was treated with 12.5 - 200 µM of
probenecid and 10 µM of Hoechst 33342 for 30 min and rinsed with ice cold D-PBS,
followed by fluorescence intensity reading from the microtiter plate reader (n=6). Increase
in blue fluorescence intensity indicated that there is an accumulation of Hoechst 33342 in
ReNcell VM due to the inhibition of MRP1 transporter by probenecid.
Therefore, we selected verapamil, probenecid, and novobiocin as selective inhibitors
of MDR1, MRP1, and BCRP to determine the transporter activity in 3D-cultured ReNcell
VM. Blocking of these transporters with the inhibitors could result in accumulation of
Hoechst 33342, the fluorescent transporter substrate, inside the cells, leading to an increase
in blue fluorescence intensity with increasing concentrations of the inhibitors (Figure
3.11). Thus, transporter activity was determined based on the increase in blue fluorescence
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intensity of inhibitor-treated ReNcell VM at varying concentrations of the inhibitors. The
TAF of ABC transporters in ReNcell VM was determined at the highest concentration of
the inhibitors (i.e., 200 µM verapamil, 200 µM probenecid, and 400 µM novobiocin).
Relatively high TAFs (30% and 22%) were observed for MDR1 and MRP1 as compared
to BCRP, demonstrating that MDR1 and MRP1 transporter activities are increased in 3Dcultured ReNcell VM (Figure 3.12). Interestingly, there was significant difference between
2D- and 3D-cultured ReNcell VM in terms of MDR1 activity. The TAF of MRP1 was high
(30% and 22%) for both 2D- and 3D-cultured ReNcell VM, which was well correlated with
the result of RNA-Seq analysis where high expression of MRP1 transporter was observed
as compared to the expression level of MDR1 and BCRP transporters (Figure 3.13).
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Figure 3.11. Inhibition of MDR1, MRP1, and BCRP transporters in (A) 2D- and (B)
3D-cultured ReNcell VM with varying concentrations of specific inhibitors. ReNcell
VM in both 2D (n=6) and 3D culture (n=12) were exposed to six concentrations of
verapamil, probenecid, and novovbiocin for the inhibition of MDR1, MRP1, and BCRP
transporters with 10 µM of Hoechst 33342, the fluorescent transporter substrate.
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Figure 3.12. Average TAF of MDR1, MRP1, and BCRP transporters in (A) 2D- and
(B) 3D-cultured ReNcell VM. The accumulation of Hoechst 33342 in ReNcell VM was
determined using the highest concentration of verapamil (200 µM), probenecid (200 µM),
and novobiocin (400 µM), respectively. Unlike the other transporters, there might be
MDR1 overexpressed in 3D-cultured ReNcell VM.
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Figure 3.13. Gene expression levels of major ABC transporters in ReNcell VM
visualized in Clustergrammer after processing RNA-Seq data. Among the three
transporters tested, only MRP1 was expressed higly as compared to the expression level of
MDR1 and BCRP, which is consistent with what we discovered in Figure 3.10A.
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3.4. Discussion
Ion channels and ABC-transporters have emerged as attractive drug targets in
modern drug discovery [167], [176]–[179]. In this study, we established high-throughput
fluorescent assays for the assessment of ion channel and transporter activities in 3Dcultured ReNcell VM on a 384-pillar plate. We implemented RNA-Seq analysis to identify
gene expression levels of ion channels and transporters in ReNcell VM. RNA-Seq enables
the discovery, quantification, and profiling of RNAs, thereby providing information on the
expression level of each gene in a cell. The expression level of mRNA in a cell is indicative
of the potential expression levels of proteins in the cell. Therefore, depending on the
relative gene expression levels of major ion channels and ABC-transporters from RNASeq, we were able to select specific inhibitors/blockers as test compounds to measure the
activity of ion channels and transporters in ReNcell VM and establish high-throughput, 3D
NSC-based, ion channel and efflux transporter assays.
The minimal expression of voltage-gated ion channels and major efflux transporters in
ReNcell VM observed from RNA-Seq was consistent with literature [180]–[185] where
minimal expression of functional channels such as voltage-gated sodium and calcium
channels or receptors in progenitor cells from the nervous system has been reported when
grown under proliferative conditions. This can be attributed to the fact that proliferation
and functional expression of ion channels or receptors may not occur at the same time
[180]. This may be the reason why voltage-gated sodium channels are not expressed in
embryonic human neural progenitor cells and neonatal neural progenitor cells [181]. In
addition, the expression of voltage-gated potassium channels and the absence of voltagegated sodium channels in ReNcell VM discovered from our study are consistent with
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literature. For example, Cho et al. reported the expression of both tetraethylammonium
(TEA)-sensitive delayed rectifying potassium channel and inwardly rectifying potassium
channel with no expression of sodium channel in human NSC cell line [182]. Likewise,
Piper et al. found that cultured human NPCs express 4-aminopyridine (4-AP)-sensitive and
delayed-rectifier type potassium currents with no observed expression of sodium channel
currents under non-differentiating conditions. On the other hand, the majority of them
expressed inward tetrodotoxin-sensitive and resistant sodium currents, sustained calcium
currents, inwardly rectifying potassium currents) and outward time- and voltage-dependent
currents and neuronal markers upon differentiating the cells [183]. Thus, the absence of
sodium currents combined with the presence of voltage-activated potassium currents might
be one of the characteristic features of NSCs/NPCs [182], [183].
Fluorescent assays enable functional readout of ion channel activity over time in highthroughput platforms [186]. The assays that measure intracellular ionic concentrations are
widely used in research and for HTS of ion channel modulators [162]. We initially focused
on establishing a high-throughput potassium ion channel assay in 3D-cultured ReNcell VM
with FluxOR potassium channel assay kit because of the expression levels of voltage-gated
potassium channels (Kv) and the important role of Kv channels in various physiological
processes. The FluxOR assay relies on measuring changes in ion concentrations in the
intracellular compartment, resulting from potassium ion channel activity. Thallium ions
can permeate potassium ion channels and have been substituted for potassium ions in the
assay to provide an enhanced signal-to-background ratio [187]–[189]. Kv channels are
generally involved in the regulation of membrane potential, cell volume, proliferation, and
apoptosis in a wide range of cells [181]. In addition, disruption of even a subtype of
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potassium ion channels can result in neurodegenerative diseases such as Alzheimer’s and
Parkinson’s diseases. Due to this important physiological role played by potassium ion
channels, it has been used as a therapeutic target for various diseases. The high expression
levels of Kv 4.3 and Kv 7.2 in ReNcell VM from RNA-Seq analysis in our study were
correlated well with other studies, indicating that they are highly expressed in the human
brain [190]. The inhibitor of KCNQ2 channel, XE-991, has been extensively used to block
the Kv 7.2/KCNQ2 channel in several in vitro and in vivo studies even though there has
been no clinical trials conducted for this compound [191]–[193]. On the other hand,
fluoxetine is a selective serotonin reuptake inhibitor used for treating depression with
relatively few side effects [194]–[196]. The effects of fluoxetine on voltage-gated channels
have been widely studied [197], [198]. Jeong et al. investigated the effects of fluoxetine on
cloned Kv4.3 channels expressed in CHO cells using the whole-cell patch-clamp technique
and reported that fluoxetine blocked Kv4.3 in a concentration-dependent manner with IC50
of 11.8 µM [198]. Our result was correlated with the literature, with more than 20%
inhibition observed at 100 µM. In addition, the concentration of fluoxetine in the brain
seems to be 20 times higher than the corresponding blood level because of high
lipophilicity of the drug [198], [199].
The function of store-operated calcium channels (SOCCs) indicates the inverse relation of
calcium ion concentrations in the endoplasmic reticulum (ER) with the rate at which
calcium ions cross the plasma membrane and enter the cell [174]. Given the
neuroectodermal lineage and non-excitable nature of neural stem/progenitors cells, SOCCs
play an important role for neurodevelopmental processes including neurogenesis,
proliferation, and migration [200]. Fluorescence-based measurement of calcium ions is
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shown to be robust for monitoring the activity of SOCCs [201]. Fluo-4 Direct calcium
assay, in particular, allows direct addition of the fluorescence reagent in microtiter well
plates, without the need for medium removal and wash steps, and is commonly used for
high-throughput assessment of calcium channel activities [202], [203]. 2-APB is one of the
most widely studied compound for SOCC modulation, which acts as both the activator and
the inhibitor of SOCCs [174], [201], [204]. The biphasic response from 2-APB observed
in 2D- and 3D-cultured ReNcell VM is in line with literature that have shown the biphasic
action of 2-APB in SOCCs where lower concentration ranges in 1 - 20 µM enhanced storeoperated entry whereas higher concentration range in 25 - 100 µM blocked SOCCs [174],
[201], [204]. In addition, this complex pharmacological action of 2-APB has not only been
shown to be related to applied concentrations but also in the pH levels and cell types [205].
For example, Takahasi et al. reported that 2-APB at 100 μM inhibited SOCCs at pH 7.4
whereas it enhanced the store-operated calcium entry at pH 6.5, indicating the dual mode
action of 2-APB dependent on external pH [206], [207]. Likewise, in many cell types, the
activation of phospholipase C through G protein-coupled receptors liberates calcium ions
from the lumen of the ER, resulting in the activation of SOCCs [175].
Efflux transporters including MDR1, MRP1, and BCRP from the ABC transporter family
play a major role in drug disposition, limiting the uptake of drugs in target cells and tissue
barriers such as the blood-brain barrier [208]. Traditionally, the identification of substrates
and inhibitors of ABC efflux transporters and the assessment of their activities has been
performed using membrane-based assays, which are prepared from cells expressing ABC
transporters [171]. However, these assays are low throughput and do not represent the
native transporter expression in the human brain. Therefore, the 3D NSC-based transporter
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assay established on the 384-pillar plate is not only high throughput but also provides
functional readout of transporter activities and transporter/substrate interactions [171].
RNA-Seq analysis of ReNcell VM revealed minimal expression of ABCB1 (MDR1) and
ABCG2 (BCRP) genes and some levels of expression of ABCC1 (MRP1) gene in our
study. This result is in contrary to previous studies where higher levels of ABCB1 and
ABCG2 gene expression in human neural stem/progenitor cells have been reported [209]–
[211]. On the other hand, ABCC1 (MRP1) was found to be expressed highly as compared
to the expression levels of the other two efflux transporters. ABCC1 (MRP1) transporters
are known to be expressed in the human brain and are involved in removal of endogenous
substances and toxic organic anions [184], [185]. In our study, MK-571 did not selectively
inhibit the MRP1 transporter for both calcein AM and Hoechst 33342 fluorescent
substrates, indicating that MK-571 is a non-selective inhibitor of ABC transporters
commonly used to inhibit over-expressed MRP transporters [168]. Probenecid on the other
hand, has been shown to be a selective inhibitor of MRP1 transporter [212]. The TAF
enabled the comparison of the activity of efflux transporters including MDR1, MRP1, and
BCRP among different samples or cell lines [172], [213]. In addition, the TAF of the three
ABC-transporters in our study was correlated with the mRNA expression level of those
transporters in ReNcell VM identified from RNA-Seq analysis. As the TAF is unitless, the
theoretical range is considered to be between 0 to 100 where TAF values > 25 are
considered clinically relevant and the cells/specimens are regarded as multi-drug resistance
positive whereas with TAF values < 25, the cells/specimens are considered multi-dug
resistance negative [172], [213]. In positive control cells, the TAF values can go up to 95 98 [214].
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3.5. Conclusions
We have successfully established fluorescence-based assays on a 384-pillar plate with 3Dcultured ReNcell VM for high-throughput compound screening for ion channels and
transporters. RNA-seq analysis was used to identify ion channels and transporters
expressed in ReNcell VM. Only few ion channels and one major ABC transporter was
found to be expressed comparatively higher than other functional channels and
transporters. Voltage-gated potassium channel and store-operated calcium channel assay
was established, and activity of those channels were measured in 3D-cultured ReNcell VM
using the known inhibitors of the respective channels. Similarly, ABC-transporter assay
was established and TAF was measured for the respective transporter in 3D-cultured
ReNcell VM. It is important to develop 3D cell models on HTS systems that can offer
highly predictive information at low costs. In the future, we will investigate the effect of
unknown compounds on the modulation of ion channels and transporters, and their
influence on physiological functions of 3D-cultured NSCs such as proliferation,
differentiation, and migration. Rapid, direct, and reliable measurement of compound
effects on ion channels and transporters can be used for drug discovery and environmental
toxicant screening.
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CHAPTER IV
ESTABLISHMENT OF HIGH-CONTENT IMAGING (HCI) ASSAYS IN 3DCULTURED NSC MICROARRAYS FOR THE ASSESSMENT OF
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4.1. Introduction
Neurodevelopmental disorders including autism, attention deficit hyperactivity disorder,
dyslexia, and other cognitive impairments have been increasing in recent years [215].
Environmental toxicants including heavy metals, pesticides, and herbicides accumulated
in the body presumably play an important role in developmental neurotoxicity (DNT).
However, only a limited number of compounds have been tested for DNT among a large
number of chemicals available in the market [2], [10], [62]. Out of 80,000 – 100,000
chemicals in the market, only about 150 chemicals have been subjected to international
DNT guidelines [10], [13], [62]. The lack of information and studies can be attributed to
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the current guidelines for DNT which are based entirely on in vivo experiments. In vivo
studies for each chemical requires approximately 700 rodents, costs nearly $1 million, and
could take more than a year, making it not only expensive and time-consuming but also
ethically questionable [10], [11], [13]. In addition, due to the species-specific difference
and the lack of knowledge on pharmaco-/toxicodynamics between rodents and humans, the
predictivity of DNT in humans from in vivo animal studies is uncertain [7], [14], [15].
Therefore, alternative in vitro test methods which are cost-effective, high-throughput, and
predictive, based on human-specific toxicity pathways, are required to close the gap [11],
[20]. Mechanism-based, target-specific endpoints are required to predict the neurotoxicity
of compounds including drug candidates and environmental toxicants in humans [216].
High-throughput screening (HTS) systems implemented for DNT testing of a large
number of chemicals should be capable of analyzing the adverse effects on cell and
organelle levels [55], [215], [217]. High-content imaging (HCI) assays are indispensable
when it comes to high-throughput assessment of DNT as they provide multi-parametric
information on cellular functions that play pivotal roles in DNT [62]. HCI analyzes targetspecific endpoints (e.g., mitochondrial membrane potential, intracellular glutathione level,
oxidative stress, apoptosis/necrosis), morphological changes, and reporter signals thereby
improving understanding of the mechanism of action of drug candidates and environmental
toxicants. However, HCI assays performed on two-dimensional (2D) cell monolayers limit
the predictability of in vivo toxicity due to inaccurate representation of in vivo tissue
structure. Cells in 2D cultures are restricted in various aspects of cell-cell and cell- matrix
interactions that are crucial for maintaining regular cell functions, and lack in vivo
phenotypic and genotypic characteristics [218].

76

On the other hand, three-dimensional (3D) cell cultures better mimic the physiology
of human tissues. Therefore, HCI assays performed on 3D-culture cells can potentially
provide better understanding of its morphological and functional features. This further aids
in the evaluation of toxicity of drug candidates and environmental toxicants in vivo.
However, current 3D cell culture systems lack the throughput required for screening DNT
against a large number of chemicals [219]. To overcome these limitations, we have
developed miniature 3D neural stem cell (NSC) cultures on a unique 384-pillar plate that
allows high-throughput, HCI assays to better predict DNT in humans. Stem cells including
embryonic stem cells and induced pluripotent stem cells have been used as cellular models
for drug discovery and toxicology studies [130]. Among the stem cell models, human
neural stem/progenitor cells are suggested as a highly predictive cellular model for
neurotoxicity testing [7], [62], [220], due to their ability to proliferate and differentiate into
multiple neural lineages from different regions of developing brains [182], [221], [222].
We have recently developed a 384-pillar plate that can be coupled with standard
384-well plates for high-throughput, 3D cell-based, metabolism-induced toxicity assays
[223]. Our goal in this study is to demonstrate the HCI capability of the 384-pillar plate
using 3D-cultured ReNcell VM for assessing DNT of compounds. Four model compounds
have been evaluated against multiple parameters, including mitochondrial membrane
impairment, intracellular glutathione levels, cell membrane integrity, DNA damage, and
apoptosis, using dyes such as tetramethyl rhodamine methylester (TMRM),
monochlorobimane (mBCl), calcein AM, Hoechst 33342, and YO-PRO-1, respectively.
Finally, IC50 values have been calculated from the dose-response curves obtained to
establish 3D HCI assays on the 384-pillar plate.
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4.2. Materials and Methods
4.2.1. Human neural stem cell (NSC) culture
ReNcell VM, a human NSC line (EMD Millipore, Burlington, MA, USA) was passaged in
complete NSC medium (ReNcell NSC maintenance medium, EMD Millipore)
supplemented with 20 ng/mL epidermal growth factor (EGF, EMD Millipore), 20 ng/mL
basic

fibroblast

growth

factor

(bFGF,

EMD

Millipore),

and

1%

(v/v)

penicillin/streptomycin (Thermo Fisher, Waltham, MA, USA) on laminin-coated, tissue
culture-treated, T-75 flasks in a humidified 5% CO2 incubator at 37°C. The medium was
replaced every two days with freshly-prepared complete NSC medium until the cells
reached 90% confluency, after which they were detached with Accutase™ (EMD
Millipore), suspended in ReNcell NSC maintenance medium, and centrifuged at 300 g for
4 min. The resulting cell pellets were resuspended in 1 mL of complete NSC medium. The
density of ReNcells was determined using a Moxi cell counter (ORFLO Technologies,
MXZ001), and 1.5  106 cells were seeded on freshly-prepared, laminin-coated, T-75
flasks.
4.2.2. Establishment of 3D-cultured NSC on 384-pillar plate
For 3D NSC culture, 384-pillar plates (MBD, South Korea) were coated with 0.01% (w/v)
poly(maleic anhydride alt-1-octadecene) (PMA-OD) and dried for at-least 4-6 h at room
temperature. A mixture of 0.0033% (w/v) poly-L-lysine (PLL) and 25 mM calcium
chloride (CaCl2) was prepared in sterile deionized water and printed on top of the PMAOD-coated 384-pillar plates at a volume of 2 µL with a microarray spotter (S+ Microarrayer
from Samsung Electro Mechanics Co. or SEMCO, Suwon, South Korea). NSC medium
plates were prepared by dispensing complete NSC medium into 384-well plates (Corning)
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at a volume of 50 µL per 384-well and incubated in the 5% CO2 incubator at 37°C for later
use. For 3D NSC culture on the 384-pillar plate, the suspension of ReNcell VM was mixed
with 3% (w/v) low-viscosity alginate (Sigma-Aldrich) and 15 mg/mL growth factor
reduced (GFR) Geltrex® (ThermoFisher) to achieve a final cell concentration of 2106
cells/mL in 0.75% (w/v) alginate and 2.5 mg/mL Geltrex and stored on ice until printing.
The suspension of ReNcell VM in the alginate-Geltrex mixture was then printed on top of
dried PLL/CaCl2 spots at a volume of 2 µL (4,000 cells per 384-pillar) while maintaining
the slide deck at 7°C to prevent water evaporation during printing. The 384-pillar plates
were left on the chilling slide deck for 4 min for gelation and then sandwiched with the
384-well plates containing 50 µL of complete NSC medium per 384-well. The sandwiched
384-pillar/well plates were incubated in the 5% CO2 incubator at 37°C.
4.2.3. Compound treatment on 3D-cultured NSC
Four model compounds including rotenone, 4-aminopyridine, digoxin, and topotecan (all
from Sigma-Aldrich) with different mechanisms of action were selected to demonstrate
high-throughput assessment of mechanistic neurotoxicity on the 384-pillar plate platform.
These compounds were selected based on previous information of their ability to induce
cell death through various mechanisms (Table 2). A powder form of each compound was
dissolved in DMSO to prepare compound stock solutions. Five concentrations of each
compound with 4-fold serial dilution, and one DMSO-alone control, were prepared to
obtain dose response curves and calculate IC50 values. The concentration ranges of the
compounds used were as follows: rotenone (0.16 – 40 µM), 4-aminopyridine (19.5 – 5,000
µM), digoxin (0.04 – 10 µM), and topotecan (0.08 – 20 µM). The dosage range of these
compounds were selected based on their known IC50 values obtained from literature. The
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compounds at five dosages and one control were dispensed at a volume of 50 µL/384-well
with 12 replicates per concentration in a 384-well plate. For the assessment of mechanistic
neurotoxicity, the 384-pillar plate pre-incubated for 72 h was sandwiched with the 384well plate containing compounds, and then incubated in the 5% CO2 incubator for 24 h at
37C.
Table 2. The four model compounds with their classifications and concentration
ranges used in this study.
Compound

Classification

Mechanisms of action
[Reference]

Test conc.
(µM)

Rotenone

Pesticide,
insecticide, and
piscicide

AP, MI, OS
[224], [225]

0.16 – 40

4- Aminopyridine
(4-AP)
Digoxin

MI, OS, PCB,
Vertebrate pesticide (Glover 1982; Jensen et al. 2014; 19.5 – 5,000
Soares et al. 2018)
AP, OS
Inotropic agents
0.04 – 10
[229], [230]

Chemotherapeutic
AP, TI
0.08 – 20
drug
[231]–[233]
Abbreviations: mitochondrial impairment (MI), oxidative stress (OS), apoptosis (AP),
potassium channel blocking (PCB), and topoisomerase inhibition (TI).

Topotecan

4.2.4. HCI assays of 3D-cultured NSC on 384-pillar plate
Multiple endpoints including mitochondrial impairment with TMRM, DNA damage with
Hoechst 33342, decrease in intracellular glutathione level with mBCl, cell membrane
integrity with calcein AM, and apoptosis with YO-PRO-1, were evaluated for the
determination of mechanisms of compound-induced neurotoxicity. Stock solutions of
fluorescent dyes were prepared in DMSO at the following concentrations: 0.5 mM TMRM,
10 mM Hoechst 33342, 200 mM mBCl, 1 mM calcein AM, and 1 mM YO-PRO-1. After

80

24 h incubation with the model compounds, the 384-pillar plate with 3D-cultured ReNcell
VM was rinsed twice for 5 min each by sandwiching it with a 384-well plate containing 50
µL of the saline solution, followed by staining with 50 µL per 384-well of the fluorescent
dye solutions in a 384-well plate for 1 h at room temperature. Final working concentrations
of fluorescent dyes (0.5 µM TMRM, 10 µM Hoechst 33342, 200 µM mBCl, 0.25 µM
calcein AM, and 10 µM YO-PRO-1) were obtained by diluting the dyes in the saline
solution containing 140 mM of NaCl and 20 mM CaCl2 in sterile deionized water. After 1
h incubation, excess dyes in the cell spots were removed by rinsing it twice with the saline
solution in 384-well plates for 10 min. Apoptosis was assessed with YO-PRO-1 staining
after 6, 12, and 24 h of incubation with the compounds.
4.2.5. Image acquisition of 3D-cultured NSC on 384-pillar plate
Images of 3D-cultured ReNcell on the 384-pillar plate were acquired in high-throughput
with an automated fluorescence microscope (S+ scanner from SEMCO, South Korea). The
S+ scanner contains four filter channels for detecting multicolor, blue, green, and red
fluorescent dyes, individually or simultaneously. Fluorescent images stained with different
fluorescent dyes were obtained with appropriate filters: TMRM stained cells with the red
filter, Hoechst 33342 and mBCl stained cells with a blue filter (DAPI-5060C from
Semrock), and calcein AM and YO-PRO-1 stained cells with the green filter. A 4 objective
lens (UPLFLN 4X, Olympus, Japan) was used to obtain the image of the entire cell spots
from the 384-pillar plate. Exposure times for the filter channels were adjusted based on
histogram to obtain optimum fluorescence intensity and prevent photobleaching of the
fluorescent dyes.
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4.2.6. Image processing and data analysis
Images obtained from the HCI assays were processed using a batch processing macro
developed in ImageJ for the extraction of fluorescence intensity, following the method
published previously [131]. The intensity data were further analyzed using GraphPad Prism
(GraphPad Software, San Diego, CA), except for the intensity data obtained from the
apoptosis assay, to determine the concentration-dependent effect of the four model
compounds. The data obtained from the apoptosis assay was analyzed using SigmaPlot
software to measure both concentration- and time-dependent effects of the compounds on
ReNcell VM apoptosis. Changes in fluorescence intensity from TMRM, Hoechst 33342,
mBCl, and calcein AM were evaluated to determine mitochondrial impairment, DNA
damage, intracellular glutathione level, and cell membrane integrity, respectively. Since the
background fluorescence of completely dead ReNcell VM (following treatment with 70%
methanol for 1 h) was negligible due to background subtraction, the percentage of live
ReNcell VM was calculated using the following equation:

% 𝐋𝐢𝐯𝐞 𝐜𝐞𝐥𝐥𝐬 = [

𝑭𝑹𝒆𝒂𝒄𝒕𝒊𝒐𝒏
] 𝐱 𝟏𝟎𝟎
𝑭𝑴𝒂𝒙

where FReaction is the fluorescence intensity of the spot exposed to the compounds and FMax
is the fluorescence intensity of fully viable cells. The fluorescent intensities of all the cell
spots were normalized with respect to the fluorescent intensity of fully viable cells (i.e.,
cell spots in control) to generate sigmoidal dose-response curves with response values
ranging from 0 to 100% plotted against the logarithm of test concentrations. The sigmoidal
dose-response curves and IC50 values (concentration of the compound where 50% of
cellular mechanism is inhibited) were obtained using the following equation:
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𝐘 = 𝐁𝐨𝐭𝐭𝐨𝐦 + [

𝑻𝒐𝒑 − 𝑩𝒐𝒕𝒕𝒐𝒎
]
𝟏 + 𝟏𝟎(𝑳𝒐𝒈𝑰𝑪𝟓𝟎 −𝑿)×𝑯

where IC50 is the midpoint of the curve, X is the log concentration of test compound, H is
the hill slope, and Y is the cellular response (% live cells), starting from the top plateau
(Top) of the sigmoidal curve to the bottom plateau (Bottom) [223].
4.2.7. Calculation of the Z’ factor and the coefficient of variation (CV)
Robustness and reproducibility of HCI assays on the 384-pillar plate was established by
calculating the Z′ factor and the coefficient of variation (CV). The Z′ factor was calculated
using the following equation:
𝐙′ =

(𝑨𝒗𝒈𝑴𝒂𝒙 − 𝟑𝑺𝑫𝑴𝒂𝒙 ) − (𝑨𝒗𝒈𝑴𝒊𝒏 + 𝟑𝑺𝑫𝑴𝒊𝒏 )
𝑨𝒗𝒈𝑴𝒂𝒙 − 𝑨𝒗𝒈𝑴𝒊𝒏

where AvgMax is the average of all maximum fluorescence intensity from fully viable
ReNcell VM on the 384-pillar plate, SDMax is the standard deviation of maximum
fluorescence intensity, AvgMin is the average of all minimum fluorescence intensity from
the dead cells affected by the highest dose of highly cytotoxic compound (topotecan), and
SDMin is the standard deviation of minimum fluorescence intensity. The reproducibility of
HCI assays on the 384-pillar plate was measured using the coefficient of variation (CV)
which is the ratio of the standard deviation (SD) to the average (Avg).
𝐂𝐕 =

𝑺𝑫
× 𝟏𝟎𝟎
𝑨𝒗𝒈

It represents variability in relation to the average signal strength, therefore the inverse of
the signal-to-noise ratio [223].
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4.2.8. Statistical analysis
To investigate the main mechanism of toxicity for the model compounds, statistical
analysis was performed with GraphPad Prism. One-way analysis of variance (ANOVA)
was used to compare the mean IC50 values of the test compounds obtained from 3Dcultured ReNcell VM. Statistically significant IC50 difference among the HCI assays was
indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001.
4.3. Results
4.3.1. Robustness of high-content imaging (HCI) assays on 384-pillar plate
HCI assays of 3D-cultured ReNcell VM on the 384-pillar plate were assessed for
robustness and reproducibility by calculating Z′ factors and the coefficient of variation
(CV: ratio of the standard deviation and the overall mean), prior to testing mechanisms of
action of the model compounds. Briefly, ReNcell VM cells printed on the 384-pillar plate
were incubated with complete NSC medium for 72 h and treated with the four model
compounds for 24 h, followed by cell staining with the fluorescent dyes. To calculate Z′
factors, AvgMax was obtained from control samples exposed to no compound, whereas
AvgMin was obtained from the cell spots exposed to the highest dose of highly cytotoxic
compound (topotecan). The calculated Z′ factors from topotecan for TMRM, mBCl, and
calcein AM staining were 0.59, 0.61, and 0.58 respectively. Since, Hoechst 33342 stained
cells showed increase in blue fluorescence intensity due to condensed nuclei, indicating
apoptosis, we could not calculate the Z′ factor for Hoechst 33342. Since 0.5  Z′  1 is
considered highly robust for an assay, the HCI assays we performed on the 384-pillar plate
platform are robust and suitable for accurately identifying mechanisms of compound
toxicity. In addition, the coefficient of variation (CV) was calculated from control samples
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exposed to no compound to measure reproducibility of cell printing and the HCI assays on
the 384-pillar plate. The fluorescence intensity obtained from staining 3D-cultured ReNcell
VM on the 384-pillar plate exposed to no compound was used to calculate CV values for
cell printing and day-to-day variability (Figure 4.1A). Experimental errors determined by
the CV value less than 25% are considered acceptable and reproducible. The overall CV
values obtained at different days for the TMRM, calcein AM, mBCl, and Hoechst 33342
assays were 12.4%, 11.8%, 11.3%, and 10.8% respectively, indicating that the HCI assay
performed on the 384-pillar plate platform was highly reproducible (Figure 4.1B).
(A)
(I)

(II)

(B)

(III)

(IV)

(V)

Reproducibility

20

CV (%)

15
10
5
0

March 14 Sep. 18
Dec. 18
Figure 4.1. (A) Representative fluorescent images of 3D-cultured ReNcell VM at day 4
stained with multiple fluorescent dyes: (I) Tetramethyl rhodamine methylester (TMRM),
(II) monochlorobimane (mBCl), (III) Calcein AM, (IV) Hoechst 33342, and (V) YO-PRO1. (B) Day-to-day variability of CV values determined by TMRM staining for
mitochondrial membrane potential. Triplicate 384-pillar plates with each plate containing
12 replicates of each test condition were stained and analyzed on March 14, September 18,
and December 18, 2018. The mean CV values obtained at different days were 12.9, 13.6,
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and 10.7, respectively. Thus, the overall CV value was 12.4%, indicating high
reproducibility of the assay performed on the 384-pillar plate.

4.3.2. Mechanisms of compound toxicity on 3D-cultured NSC
Mechanistic toxicity of the four model compounds was assessed by treating 3D-cultured
ReNcell VM on the 384-pillar plate with rotenone, 4-aminopyridine, digoxin, and
topotecan, followed by cell staining with the four fluorescent dyes. Fluorescent images
were obtained by using the S+ scanner, and fluorescence intensity from cell images was
quantified using the ImageJ plugin (Figure 4.2). Dose-response curves of the compounds
for the four mechanisms of toxicity were plotted by using the normalized fluorescent
intensity method (Figure 4.3). IC50 values were calculated for each compound and assay,
in which 50% inhibition of the assessed mechanism of toxicity was observed (Table 3).
For example, more than 90% impairment in mitochondrial membrane potential (MMP)
was observed from the highest concentration of both digoxin and topotecan, whereas only
60% inhibition was observed from the highest concentration of 4-aminopyridine. TMRM
is a cell permeable fluorescent dye and its accumulation in the mitochondrial matrix space
is dependent on MMP. Since MMP is regarded as a key indicator of mitochondrial health,
a decrease in TMRM fluorescence is an indicator of mitochondrial impairment [234]–
[236].
Monochlorobimane is a non-fluorescent cell permeable dye that emits blue
fluorescence only after conjugation with intracellular glutathione. Intracellular glutathione
acts as an antioxidant in mammalian cells and is subjected to depletion by the reactive
oxygen species (ROS) generated by toxic compounds [237] [238]. Therefore, a decrease in
intracellular glutathione level is an indicator of oxidative stress by the compound. Both
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topotecan and digoxin reduced nearly 60% of intracellular glutathione levels in 3Dcultured ReNcell VM. Calcein AM was used to evaluate cell membrane integrity as a
measure for cell viability [239]. Calcein AM is a hydrophobic fluorescent dye that
permeates live cells and is hydrolyzed by the intracellular esterases to calcein which emits
green fluorescence. Calcein is a hydrophilic compound that remains trapped inside the
cytosol of intact membranes. The IC50 values of topotecan in our study from the calcein
AM assay were comparable to those obtained from spheroids of glioma stem cells by
Zhang et al. [240]. As compared to major changes in MMP after compound exposure, there
were minor changes in cell membrane integrity observed at the highest dosage after 24 h
incubation with 4-aminopyridine, digoxin, and topotecan. This could be because the cells
go through apoptosis with intact cell membrane, as evidenced by YO-PRO-1 staining at
different time points. Likewise, Hoechst 33342 which binds to nucleic acid and is widely
used to assess condensed pyknotic nuclei in apoptotic cells showed an increase in blue
fluorescence intensity, indicating condensed nuclei due to apoptosis [241].
(A)

(B)

(C)

(D)

(E)

Figure 4.2. Images of 3D-cultured ReNcell VM arrays on the 384-pillar plate exposed to
varying concentrations of topotecan (0.08 – 20 µM) for 24 h and stained with four
fluorescent dyes: (A) TMRM for mitochondrial membrane potential (MMP), (B) mBCl for
intracellular glutathione (ICG) levels, (C) Calcein AM for cell membrane integrity (MI),
(D) Hoechst 33342 for DNA damage (DD), and (E) YO-PRO-1 for apoptosis. A decrease
in fluorescence intensity in (A), (B), and (C) and an increase in fluorescence intensity in
(D) with increasing compound dosages (from top to bottom) was observed from 3Dcultured ReNcell VM arrays.
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Figure 4.3. Dose response curves of (A) Rotenone, (B) 4-aminopyridine, (C) Digoxin, and
(D) Topotecan obtained from four HCI assays: (I) TMRM for mitochondrial membrane
potential (MMP), (II) mBCl for intracellular glutathione level (IGL), (III) Calcein AM for
membrane integrity (MI), and (IV) Hoechst 33342 for DNA damage (DD). The array of
3D-cultured ReNcell VM on the 384-pillar plate was exposed to rotenone (0.16 – 40 µM),
4-aminopyridine (19.5 – 5000 µM), digoxin (0.04 – 10 µM), and topotecan (0.08 – 20 µM),
for 24 h and stained with TMRM, mBCl, calcein AM, and Hoechst 33342 to obtain doseresponse curves and IC50 values.
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Table 3. Summary of IC50 values of four compounds obtained from the HCI assays on 384pillar plate.
HCI assays (Endpoints)
mBCl
Calcein AM
(IGL)
(MI)

Compound

TMRM
(MMP)

Rotenone

31.52 ± 7.33

Nontoxic

Nontoxic

NA

4aminopyridine

4.9 ± 0.45

5.9 ± 0.5

Nontoxic

NA

Digoxin

0.16 ± 0.08

2.06 ± 0.3

3.4 ± 0.8

NA

Topotecan

0.69 ± 0.01

4.24 ± 0.6

6.5 ± 1.0

NA

Hoechst 33342
(DD)

Abbreviations: mitochondrial membrane potential (MMP), intracellular glutathione level
(IGL), membrane integrity (MI), DNA damage (DD), and not applicable (NA).

Apart from indirect assessment of apoptosis via condensed nuclei with Hoechst
33342, apoptosis in 3D-cultured ReNcell VM was assessed directly from YO-PRO-1
staining. As apoptosis is a dynamic process, 3D-cultured ReNcell VM on the 384-pillar
plate was treated with the four compounds for 6, 12, and 24 h, and then stained with YOPRO-1 for 1 h. As a result, dose- and time-dependent effects on apoptosis were observed
from the compounds (Figure 4.4). For example, nearly 50 % increase in apoptosis was
observed after 12 and 24 h incubation with 5 µM topotecan as compared to the controls
(no compound). Interestingly, the percentage of apoptosis dropped at the highest
concentration of 20 µM topotecan at all the time points, possibly indicating that necrosis
could have been induced at that concentration. Similarly, digoxin demonstrated both doseand time-dependent effects on apoptosis. There was a slow and gradual increase in
apoptotic cells with increasing digoxin concentration after 6 h incubation, whereas more
rapid increase in apoptosis was observed after longer incubation (12 h and 24 h). Necrosis
was observed at  3.125 µM digoxin after 24 h incubation, as evidenced by a decrease in
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Figure 4.4. Dose-response curves of (A) rotenone, (B) 4-aminopyridine, (C) digoxin, and
(D) topotecan, obtained from the YO-PRO-1 assay for apoptosis. The array of 3D-cultrued
ReNcell VM on the 384-pillar plate was treated with varying concentrations of the four
compounds for 6, 12, and 24 h, and stained with 10 µM YO-PRO-1 for an hour to obtain
the dose-response curves.

Apoptosis was measured by the increase in fluorescence intensity relative to the
control condition. The response of each concentration of a compound was calculated from
12 replicates on a 384-pillar plate, with three independent replicates of the experiment (n
= 36 in total). The IC50 values of all four compounds obtained from different assays were
compared to evaluate the effect of compounds on 3D NSC culture on the 384-pillar plate.
Among the five assays/endpoints studied, changes in MMP was found to be the most
sensitive mechanism of toxicity based on the IC50 values compared to other assays (Fig.
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4.5). For all the four compounds, changes in MMP was found to be the most sensitive
compared to changes in IGL, MI, and DD. Therefore, MMP could be considered as an
initiator of the mechanism of toxicity.
Digoxin

Topotecan
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Log[IC50 (M)]

Log[IC50 (M)]
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0.0
-0.5

***

-1.0
-1.5
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-0.5

mBCl
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Calcein AM

TMRM

mBCl

Figure 4.5. One-way ANOVA analysis of IC50 values obtained from 3D-cultured ReNcell
VM pre-incubated for 72 h, exposed to digoxin and topotecan for 24 h, and stained with
calcein AM, TMRM, and mBCl (n=3 independent repeats, **p < 0.01, ***p < 0.001).
Statistically significant difference in IC50 values of digoxin was observed from TMRM
staining, indicating that the main mechanism of toxicity for digoxin is MMP. Statistically
significant difference in IC50 values of topotecan was observed from TMRM and mBCl
staining, indicating that the main mechanism of topotecan toxicity is MMP and IGL.

4.4. Discussion
There is an unmet need among pharmaceutical companies and regulatory agencies to
develop a highly predictive in vitro cell-based assay platform for early stage detection of
neurotoxicity. High-throughput, cell-based assay systems capable of analyzing the adverse
effect on human cells are inevitable when it comes to screening a large number of drug
candidates and potentially toxic chemicals for DNT testing [6], [9], [53], [130]. Therefore,
our goal in this study was to establish 3D-cultured NSCs on a unique 384-pillar plate and
demonstrate high-throughput HCI capability for predictive assessment of neurotoxicity.
ReNcell VM was selected as a cell model for human NSCs as the progenitor cell line
demonstrates the typical features of NSCs, such as the ability to proliferate, self-renew, and
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differentiate into neurons, astrocytes, and oligodendrocytes, which represent the lineages
from different regions of developing brains. ReNcell VM is a commercially available
human neural progenitor cell line obtained from the midbrain region of a 10-week human
fetus and immortalized by retroviral transduction with v-myc oncogene [133], [216], [242].
The 3D-cultured ReNcell arrays on the 384-pillar plate established in this study are
robust and high-throughput for studying mechanistic compound toxicity. The automated
cell printing on the 384-pillar plate combined with 3D cell culture in the 384-well plate
ensured highly reproducible outcomes for HCI assays with compounds. The mixture of
alginate and Geltrex for cell encapsulation was easily printable and biomimetic for 3D NSC
culture. Alginate is biologically inert and provides structural rigidity for cell encapsulation
and culture, while Geltrex being bioactive promotes cell-ECM interactions to support cell
growth and spheroid formation [136]. For optimum cell-cell interactions, seeding density
of 2 ×106 cells/mL was used on the 384-pillar plate, resulting in ~4000 cells per 384-pillar
in a 2 µL cell spot. The 384-pillar plate offers several unique advantages in terms of
mimicking cell-ECM interactions, ease of media change, high-throughput compound
screening, and rapid in situ cell imaging as compared to other 3D cell culture systems such
as spheroid culture in ultra-low attachment (ULA) plates, microfluidic systems, transwell
inserts, and hanging droplet plates. For example, media changing in ULA plates and
hanging droplet plates without disturbing the cell aggregates inside is challenging and often
time-consuming, leading to damage of those aggregates. Long-term culture and assays of
3D spheroids in hanging droplet plates require transferring the spheroids into a different
plate, thus making it cumbersome and low-throughput [243]. In addition, spheroid cultures
in ULA plates and hanging droplet plates often lack cell-ECM interactions which are vital
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for organotypic 3D cell cultures [244]. Moreover, most of the existing 3D cell cultures such
as ExVive 3D bioprinted human tissues from Organovo require cryo-sectioning of the
spheroids for imaging. Therefore, we envision that the 384-pillar plate and its cell printing
technology can be adopted in an industry setting for high-throughput, predictive compound
screening, critical for pharmaceutical and chemical companies.
The importance of 3D cell culture models in assessing mechanisms of action of
pharmaceutical drug candidates and environmental chemicals for neurotoxicity have been
highlighted earlier [6], [131], [216], [245]–[247]. In a recent study, Koo et al. established
a 3D brain on a chip model with multiple immortalized neuronal cells and reported the
correlation of the effect of organophosphates on in vitro 3D culture with in vivo data [245].
Similarly, Pamies et al. reported that a 3D spheroid model of NSCs recapitulates human
brain development and demonstrated the reproducible result of neurotoxicity with test
compounds for cell viability, ROS generation, and mitochondrial dysfunction [247].
Sirenko et al. performed HCI assays on 3D spheroid neural cultures in a 384-well plate
with multiple fluorescent dyes to assess cytotoxicity and mitochondrial toxicity of several
compounds, demonstrating 3D cultures as a biologically-relevant model system to study
neurotoxicity of pharmaceutical drugs and environmental toxicants [246].
Recently, our group has demonstrated the application of this 384-pillar plate
platform for the first time in metabolism-induced toxicity assays, using combinations of
HEK293 cells and drug metabolizing enzymes [223]. The current study is the first
demonstration of high-throughput, HCI capability on the 384-pillar plate with 3D-cultured
ReNcell VM for the assessment of compound-induced acute neurotoxicity. Multiple
fluorescent dyes such as TMRM, mBCl, calcein AM, Hoechst 33342, and YO-PRO-1, were
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used to establish HCI assays and understand various mechanisms of cell death in 3Dcultured ReNcell VM by evaluating the changes in mitochondrial membrane potential,
intracellular glutathione levels, cell membrane integrity, DNA damage, and apoptosis,
respectively. In particular, apoptosis is an important mechanism of cell death in the
developing nervous systems as neural stem/progenitor cells in an early development phase
systematically undergo apoptosis during the process of proliferation and differentiation into
neurons and glial cells [248], [249]. Due to the high expression of pro-apoptosis activating
proteins such as p53 in NSCs, these cells may be even more sensitive to apoptosis than
fully differentiated lineages [250]. Therefore, establishing HCI assays for the assessment
of apoptosis in NSCs through direct and indirect measures is important for DNT tests in
vitro. Considering these factors, we investigated the adverse effect of the compounds on
various mechanisms of cell death in 3D-cultured ReNcell VM. Studies have shown that the
formation of reactive oxygen species (ROS) by toxic compounds leads to a decrease in
antioxidant levels, reducing the level of intracellular glutathione [238]. A decrease in the
glutathione level further increases the accumulation of ROS, thereby damaging
mitochondria and nucleus, and eventually resulting in cell death [88]. In addition, the
formation of ROS has been known to induce specific cell death mechanisms such as
apoptosis and necrosis [224], [251], [252]. In particular, mitochondria are highly
susceptible to oxidative damage as it is a major source of ROS production and thus a
primary target for the large amounts of ROS. Mitochondrial intermembrane space houses
pro-apoptotic factors such as cytochrome c and apoptosis-inducing factor (AIF) which act
in caspase-dependent and caspase-independent manners, respectively [253]. When
mitochondrial membranes are disrupted, cytochrome c is released to cytosol, which binds
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to Apaf-1 and induces caspase activation in the presence of ATP [254], whereas AIF when
released from mitochondria enters the nucleus and activates nuclear endonucleases, leading
to chromatin condensation and DNA degradation and ultimately resulting in cell death
[224]. Therefore, MMP is a highly sensitive assay to study the mechanism of cell death in
neurotoxicity. Undoubtedly, the MMP assay was shown to be the most sensitive assay
among the other HCI assays tested for all four compounds.
The mechanisms of toxic action identified through HCI assays are defined as
biologically relevant series of key events/endpoints that ultimately lead to adverse
outcomes in vivo [255]. Therefore, DNT-specific in vivo processes can be linked to the
changes in various cellular processes such as apoptosis, necrosis, differentiation, and
proliferation due to the mechanisms of toxic action that occur at cellular and organelle
levels, and thus can be recapitulated with various in vitro endpoints. [6], [82]. For example,
inhibition of mitochondrial complex I leading to mitochondrial dysfunction has been
known to induce motor deficit disorder [82]. Moreover, the brain is known to be highly
sensitive to oxidative stress due to low levels of antioxidants and high levels of oxygen
consumption. Various opioids and psychostimulant drugs have been shown to trigger
oxidative stress and apoptosis via mitochondrial dysfunction. These evidences further
bolster the need for in vitro assays which identify various mechanisms of toxicity to predict
the effect of toxic chemicals in human brains [256].
The four model compounds used in this study were selected to demonstrate various
mechanisms of toxicity. Rotenone, a common insecticide and pesticide, is known to inhibit
the mitochondrial respiratory chain at the complex I site and cause ROS generation. As
discussed earlier, accumulation of ROS decreases the glutathione level, resulting in
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oxidative stress and disrupting the mitochondrial membrane. This damage in the
mitochondrial membrane has been shown to release cytochrome c and induces apoptotic
cell death [225]. However, some studies have reported the inhibition of respiratory chain
reactions by rotenone-induced necrotic cell death as characterized by intact chromatin and
loss of plasma membrane integrity [224], [257]. Therefore, rotenone-induced cell death is
variable and depends on multiple factors such as concentration, duration of exposure, and
cell type [224]. Jin et al. reported rotenone-induced mitochondrial damage in dopaminergic
cells via caspase-3 activation [225], whereas Li et al. reported caspase 9/3-independent cell
death in human NSCs by rotenone [224]. Interestingly, we observed a high level of
apoptosis in 3D-cultured ReNcells exposed to rotenone for 24 h even at relatively low
concentrations, which was comparable to the results of digoxin and topotecan. The effect
of rotenone on the other assays was not noticeable as compared to other highly toxic
compounds used in this study.
4-Aminopyridine was initially developed as an avicide (Avitrol®) in 1960s. It
causes birds to emit distress calls and has been reported to only kill about 1% of the animals
when used within the dosage range [258], [259]. However, in the later years it gained wide
applications as a treatment for multiple sclerosis. It is a potent potassium channel blocker
that protects nerve conduction in demyelinated nerve fibers and improves motor function
by enhancing the neuromuscular synaptic transmission [226], [227]. Blocking of voltagegated potassium channels has been shown to have little to no effect on apoptosis of stem
cells [260], which correlated well with our observation in this study. For example, Benı´tezRangel et al. observed nearly 40% reduction in caspase activity, which is known to be the
initiator of apoptosis, in the presence of 4-aminopyridine and other potassium channel
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blockers [261]. On the other hand, Soares et al. demonstrated the effect of 4-aminopyridine
on mitochondrial activity and oxidative stress in Drosphilia melanogaster [228]. Based on
our observations, 4-aminopyridine seems to be relatively nontoxic with less than 50%
inhibition of MMP and IGL, as compared to the other model compounds with relatively
high toxicity on 3D-cultured ReNcell VM.
Both digoxin and topotecan were highly toxic with IC50 values blow µM ranges for
the sensitive assays such as MMP and IGL. Digoxin is a member of the cardiac glycoside
family of naturally derived compounds, commonly used for the treatment of heart failure
and atrial arrhythmia [229]. Cardiac glycosides have been known to induce apoptosis via
release of cytochrome c and activation of caspase cascade by the increase in Ca2+
concentration. Digoxin is known to inhibit Na+/K+ pumps causing increase in intracellular
Na+ levels by decreasing the rate of Na+ influx through the Na+/Ca2+ exchanger, which in
turn inhibits Ca2+ efflux through the Na+/Ca2+ exchanger, thereby increasing the Ca2+
concentration [262]. Various mechanisms such as calcium-dependent activation of
caspases, generation of ROS, and topoisomerase inhibition have been suggested as the
mechanisms of cell death by digoxin [229], [230]. Prassas et al. reported that digoxin
induces caspase-dependent apoptosis in multiple cell lines [229]. In our study, digoxin
demonstrated both dose- and time-dependent apoptosis with reduction in MMP as its
primary mechanism of toxicity.
Topotecan, a semi-synthetic derivative of camptothecin, is an inhibitor of DNA
topoisomerase I and has been approved for the treatment of various cancer types [263].
Inhibition of DNA topoisomerase I results in inhibition of DNA replication and
transcription that eventually leads to apoptotic cell death [231]–[233]. Studies in multiple
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neuroblastoma cell lines reported that cytotoxic activity of topotecan is highly dependent
on exposure time. For example, Chernov et al. demonstrated decreasing IC50 values for
cell viability with Presto Blue with increasing exposure time for various neuroblastoma
cell lines [233]. Similarly, Zhang et al. showed dose- and time-dependent effects of
topotecan on glioma stem cell viability and apoptosis [240]. Topotecan demonstrated both
dose- and time-dependent apoptosis in 3D-cultured ReNcell VM over a period of 24 h in
our study. In addition, we observed dose-dependent effects of topotecan on all the assays
evaluated, with the MMP assay being the most sensitive of all. Overall, our highthroughput 3D cell culture platform was suitable for HCI assays to evaluate various
mechanisms of cell death in human NSCs from model compounds, which can be
implemented for large-scale screening of neurotoxicity.
4.5. Conclusions
We have successfully demonstrated HCI capability in 3D NSC culture on 384-pillar plate
for the first time for the assessment of predictive neurotoxicity. The 3D-cultured ReNcell
VM on the 384-pillar plate with five HCI assays, including TMRM, mBCl, calcein AM,
Hoechst 33342, and YO-PRO-1 for the evaluation of mitochondrial impairment,
intracellular glutathione level, cell membrane integrity, DNA damage, and apoptosis,
respectively, generated reproducible data for the assessment of DNT. The HCI assays
performed on 3D NSC culture on the 384-pillar plate may need further validation with
many model compounds to calculate sensitivity and specificity. With additional DNTspecific endpoints such as proliferation, migration, neurite outgrowth, and synapse
formation, our high-throughput, 3D cell culture platform can be implemented for largescale screening of drug candidates and environmental toxicants in an industry setting.
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CHAPTER V
HIGH-THROUGHPUT ASSESSMENT OF METABOLISM-MEDIATED
NEUROTOXICITY BY COMBINING 3D-CULTURED NEURAL STEM CELLS
AND LIVER CELL SPHEROIDS
5.1. Introduction
Systematic testing of developmental neurotoxicity (DNT) is not mandatory for the
regulatory assessment of chemicals in the USA and EU. It is only performed when there is
clear evidence of neurotoxicity in systemic acute toxicity or repeated dose studies or based
on chemical structure similarity with previously known toxicants [6]. Testing of chemicals
for their potential to cause DNT is primarily based on guidelines that require in vivo animal
studies. In addition, these in vivo animal studies do not generate mechanistic data required
for scientifically based human-risk assessment. Therefore, significant efforts have been
made for validating in vitro and in silico methods in predicting the neurotoxicity of
chemicals in humans, ultimately for reducing the use of animals [6], [223]. To this end, a
wide range of in vitro systems have been developed to study the effects of neurotoxicants
on various cellular functions relevant to the events in humans [264].
High-throughput screening (HTS) with two-dimensional (2D) cell monolayers and
preclinical evaluations with animal models are often inaccurate due to the lack of
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correlations between in vitro cell models and in vivo animal models and differences in
genetic makeups between animals and humans. In addition, the poor predictivity of in vitro
models to in vivo models can be attributed in part due to the lack of multicellular models
with biotransformation capability. Chemicals can be transformed into their metabolites by
drug-metabolizing enzymes (DMEs) in the liver, some of which can be severely toxic to
organs including the brains [16], [265]. Therefore, it is important to maintain
physiologically relevant levels of DMEs in HTS assays and understand the roles of these
enzymes in human toxicology [223]. However, despite the knowledge of biotransformation
playing an important role in the augmented toxicity of chemicals, relatively little efforts
have been made to incorporate biotransformation into an in vitro neurotoxicity testing
system. Conventional in vitro systems for neurotoxicity tests lack the capability of
investigating the qualitative and quantitative differences between parent chemicals and
their metabolites in the human body [265].
To the best of our knowledge, no high-throughput, in vitro methods for evaluating
metabolism-mediated neurotoxicity of chemicals have been developed and validated,
emphasizing the urgent need for predictive in vitro neurotoxicity test systems [264].
Existing in vitro hepatotoxicity test models including liver microsomes, recombinant
DMEs, primary hepatocytes, isolated liver slices, and transformed hepatic cell lines (e.g.,
THLE2, HepG2, Hep3B, etc.) are limited to testing neurotoxicity [264], [266]–[268]. For
examples, isolated enzymes such as liver microsomes and recombinant DMEs lack the
correlation of metabolic activity with in vivo metabolism [269], liver slices are difficult to
obtain in consistent quantities and qualities and rapidly deteriorated [267], [268], hepatic
cell lines express low levels of DMEs [270], and primary hepatocytes have limited lifespan
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and are difficult to maintain high DME activity [269], [271]. In addition, there is lack of
hepatic and neural cell co-culture systems that can be easily adopted in HTS of chemicals.
Therefore, there is an urgent need to develop an in vitro toxicity screening system that can
incorporate hepatic biotransformation of chemicals and predict the susceptibility of their
metabolites to induce neurotoxicity [272]. Co-cultures of metabolically competent hepatic
cells with neural cells can be of critical importance for screening test compounds
susceptible to cytochrome P450 enzymes (CYP450s) metabolism [272]. However,
simulating metabolism-mediated neurotoxicity in vitro is a challenging task due to
reduction in activities of specific DMEs in the in vitro system as compared to their activities
found in the liver. To address these issues, we adopted 3D cultures of metabolically
competent and consistent hepatic cells such as a HepaRG cell line with neural stem cells
(NSCs) such as ReNcell VM and established a high-throughput, metabolism-mediated
neurotoxicity testing system. Spheroids of HepaRG cells were generated in an ultra-low
attachment (ULA) 384-well plate and 3D-cultured ReNcell VM was established by printing
ReNcell VM in hydrogel on a 384-pillar plate with 4 sidewalls and 4 slits (384PillarPlate).
To demonstrate the proof of concept of metabolism-mediated neurotoxicity, model
compounds were added in the ULA 384-well plate with HepaRG spheroids, which was
coupled with the 384PillarPlate with 3D-cultured ReNcell VM. This simple and
straightforward approach allows us to generate metabolites in situ by HepaRG cells and
systematically test them against ReNcell VM by incorporating high-content imaging (HCI)
assays for various cellular functions. We envision that this approach can be widely adopted
in pharmaceutical and chemical industries for HTS of compounds and their metabolites for
the assessment of neurotoxicity.
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5.2. Materials and Methods
5.2.1. HepaRG spheroid culture in ULA 384-well plate
HepaRG complete base medium with supplements (MH100, Lonza, Basel, Switzerland)
and the thawing additive (MHTAP, Lonza) were warmed in a 37°C water bath for 30 min.
A complete thawing medium was prepared by adding 11.8 mL of MHTAP in 100 mL of
MH100. NoSpin HepaRG™ cells (Lonza) were transferred into a 50 mL conical tube
containing 7.5 mL of the warm thawing medium. HepaRG cell suspension at 1 million
cells/mL was prepared by gently pipetting the solution up and down and seeded in an ultralow attachment (ULA) 384-well plate (Corning, USA) (Figure 5.1B) at 5000 cells/384well by dispensing 50 µL/384-well. The ULA 384-well plate was incubated for 24 h in a
humidified 5% CO2 incubator (ThermoFisher, Waltham, MA, USA) at 37°C to form
HepaRG aggregates (Figure 5.1D). After 24 h incubation, the thawing medium was
replaced with a warm maintenance medium prepared by adding the maintenance additive
(MHMET, Lonza) in MH100. The medium was changed by taking out 30 µL of the thawing
medium from each 384-well and then adding 30 µL of the fresh maintenance medium
followed by medium change every 2 days.
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(A)

(B)

(C)

(D)

Figure 5.1. Pictures of (A) the 384PillarPlate and (B) the ULA 384-well plate as well as
brightfield images of (C) 3D-cultured ReNcell VM on the 384PillarPlate and (D)
HepaRG spheroids in the ULA 384-well plate. (Scale bar: 700 µm)

5.2.2. Viability of hepatic spheroids in ULA 384-well plate
Viability of HepaRG spheroids in the ULA 384-well plate was assessed at day 3 and day 7
using CellTiter-Glo® assay kit (Promega). Briefly, an equal volume of CellTiter-Glo
reagent was added to the 384-wells containing HepaRG spheroids in the maintenance
medium and incubated for 10 min at room temperature on an orbital shaker (Fisher
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Scientific) to induce cell lysis. The lysate was transferred to an opaque white luminometer
plate (Corning) and incubated further for 10 min at room temperature to stabilize
luminescent signals. Control wells containing the maintenance medium without the
spheroids were prepared to measure background luminescence. Luminescence intensity
was measured at 560 nm with an integration time of 0.25 - 1 s using a microtiter plate
reader (Synergy H1, BioTek).
5.2.3. Human neural stem cell (NSC) culture
ReNcell VM, a human NSC line (EMD Millipore, Burlington, MA, USA) was passaged in
a complete NSC medium (ReNcell NSC maintenance medium, EMD Millipore)
supplemented with 20 ng/mL epidermal growth factor (EGF, EMD Millipore), 20 ng/mL
basic

fibroblast

growth

factor

(bFGF,

EMD

Millipore),

and

1%

(v/v)

penicillin/streptomycin (ThermoFisher) on laminin-coated, tissue culture-treated, T-75
flasks in the 5% CO2 incubator at 37°C. The medium was replaced every 2 days with
freshly-prepared complete NSC medium until the cells reached 90% confluency, after
which they were detached with Accutase™ (EMD Millipore), suspended in ReNcell NSC
maintenance medium, and centrifuged at 300 g for 4 min. The resulting cell pellets were
resuspended in 1 mL of complete NSC medium. The density of ReNcell VM was
determined using a Moxi cell counter (ORFLO Technologies, MXZ001), and 1.5  106
cells were seeded on freshly-prepared, laminin-coated, T-75 flasks.
5.2.4. Establishment of 3D-cultured NSCs on 384PillarPlate
For 3D NSC culture, 384PillarPlates (Figure 5.1A) were coated with 0.01% (w/v)
poly(maleic anhydride alt-1-octadecene) (PMA-OD) and dried for at-least 4-6 h at room
temperature. A mixture of 0.0033% (w/v) poly-L-lysine (PLL) and 25 mM calcium
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chloride (CaCl2) was prepared in sterile deionized water and printed on top of the PMAOD-coated 384PillarPlates at a volume of 3 µL with a microarray spotter (ASFA™ spotter,
MBD Korea, Suwon, South Korea). NSC medium plates were prepared by dispensing
complete NSC medium into deep well 384-well plates (Corning) at a volume of 130 µL
per 384-well and incubated in the 5% CO2 incubator at 37°C for later use. For 3D NSC
culture on the 384PillarPlate, the suspension of ReNcell VM was mixed with 3% (w/v)
low-viscosity alginate (Sigma-Aldrich) and 15 mg/mL growth factor reduced (GFR)
Geltrex® (ThermoFisher) to achieve a final cell concentration of 2106 cells/mL in 0.75%
(w/v) alginate and 2.5 mg/mL Geltrex and stored on ice until printing. The suspension of
ReNcell VM in the alginate-Geltrex mixture was then printed on top of dried PLL/CaCl2
spots at a volume of 3 µL (6,000 cells per pillar) while maintaining the slide deck at 7°C
to prevent water evaporation during printing. The 384-pillar plates were left on the deck
for 4 min for gelation and then sandwiched with the deep well 384-well plates containing
130 µL of complete NSC medium per 384-well (Figure 5.1C). The sandwiched
384Pillar/well plates were incubated in the 5% CO2 incubator at 37°C.
5.2.5. Viability of 3D-cultured NSCs on 384PillarPlate
The viability of 3D-cultured ReNcell VM on the 384PillarPlate was measured over a period
of 10 days using a Live/Dead® viability/cytotoxicity kit for mammalian cells
(ThermoFisher). In addition, to simulate the effect of HepaRG and ReNcell VM co-culture
in HepaRG maintenance medium, viability of 3D-cultured ReNcell VM at day 7 was
assessed using the Live/Dead assay kit after exposing ReNcell VM to HepaRG
maintenance medium for 3 days. Briefly, the 384PillarPlate with 3D-cultured ReNcell VM
was separated from the 384-well plate with complete NSC medium and rinsed with a saline
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solution containing 140 mM NaCl and 20 mM CaCl2. The 3D-cultured ReNcell VM on the
384PillarPlate after exposing to HepaRG maintenance medium for 3 days was stained with
a mixture of 0.25 µM calcein AM and 1 µM ethidium homodimer-1 from the kit in a 384well plate for 1 h at room temperature. The 384PillarPlate was rinsed twice with the saline
solution to remove excess dyes, and fluorescent images were acquired in high throughput
with an automated fluorescent microscope (S+ scanner from Samsung Electro-Mechanics,
Co., Suwon, South Korea). The fluorescent cell images were obtained with a green filter
(XF404 from Omega Optical) and a red filter (TxRed-4040C from Semrock) at 4
magnification with the Olympus UPLFLN 4× (numerical aperture (NA) 0.13, f-number
26.5, and depth of field (DOF) ~ 32.3 μm) (Olympus, Tokyo, Japan). Cell images obtained
from the 384PillarPlate were batch-processed using ImageJ (NIH) to extract fluorescence
intensity from the entire cell spots and were analyzed using SigmaPlot software ver. 12
(Systat Software Inc., San Jose, CA, USA).
5.2.6. Measurement of drug-metabolizing enzyme (DME) activities in HepaRG
spheroids
CYP3A4 activity
Among representative DMEs, CYP3A4 activity in HepaRG spheroids was measured using
P450-Glo™ assay kit (Promega). Briefly, lyophilized luciferin detection reagent and the
reconstitution buffer solution were brought to room temperature and mixed together several
times to achieve a homogeneous solution. Luminogenic substrate was prepared by diluting
the luciferin-PFBE in HepaRG maintenance medium at 1: 40 dilution. For the CYP3A4
assay, the medium was removed from the 384-wells of the ULA plate and 40 L of the
luminogenic substrate solution was added. The cells were then incubated in the CO2
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incubator at 37C for 3.5 h after which 25 L/384-well of the luminogenic substrate
solution from the ULA plate was transferred into a 384-well opaque white luminometer
plate. An equal volume of reconstituted luciferin detection reagent (LDR) was added into
the wells containing the luminogenic substrate and incubated for 20 min at room
temperature, followed by luminescence measurement at 560 nm with the microtiter plate
reader.
Glutathione-S-transferase (GST) activity
The activity of GSTs in HepaRG spheroids was measured using a GST assay kit (SigmaAldrich). Briefly, HepaRG spheroids in the ULA plate were rinsed with DPBS and
incubated with 40 L of Cell Lytic™ MT (Sigma-Aldrich) for 20 min at room temperature
on the orbital shaker. The cell lysate was collected from each 384-well into a cold
microcentrifuge tubes and centrifuged for 10 min at 16,000 g to remove cell debris. The
protein-containing supernatant was transferred to a chilled microcentrifuge tube and kept
on ice until use. For the GST assay, 200 mM of L-glutathione (GSH) solution was kept on
ice while DPBS and 100 mM of 1-chloro-2,4-dinitrobenzene (CDNB) solution were kept
at room temperature. A substrate master mix was prepared by adding 200 mM of GSH and
100 mM of CDNB in DPBS to achieve a final concentration of 2 mM GSH and 1 mM
CDNB. GST control was prepared by diluting the GST solution 50-fold in a sample buffer.
The substrate master mix was dispensed in a new 384-well plate at 45 L, followed by
dispensing 5 L of the sample per 384-wells and 5 L of GST control in control wells.
Blank control was prepared by dispensing 50 L of the substrate master mix into the 384well plate. Absorbance was measured at 340 nm using the microtiter plate reader over a
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period of 30 min immediately after preparing the reaction test. GST activity was
determined by using the following equation.
∆𝑨𝟑𝟒𝟎
𝒎𝒊𝒏 × 𝑽(𝒎𝑳) × 𝒅𝒊𝒍 = 𝝁𝒎𝒐𝒍
𝜺𝒎𝑴 × 𝑽𝒆𝒏𝒛 (𝒎𝑳)
𝒎𝑳 × 𝒎𝒊𝒏
Where
∆𝐴340 𝐴340 (𝑓𝑖𝑛𝑎𝑙) − 𝐴340 (𝑖𝑛𝑖𝑡𝑖𝑎𝑙)
=
𝑚𝑖𝑛
𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 (min)
V = reaction volume (0.05 mL)
Venz = volume of the enzyme sample tested (0.005 mL)
dil = dilution factor of the original sample

mM = extinction coefficient of CDNB conjugate at 340 nm (3.6 mM-1cm-1 for a path length of
0.37 cm of the 384-well plate) [4]

UDP glucuronosyltransferase (UGT) activity
Luminescence-based UGT-Glo™ assay kit (Promega) was used to measure UGT activity
in HepaRG spheroids. All the reagents were prepared and diluted according to the
manufacturer’s protocol. Briefly, 40 µL of the HepaRG maintenance medium was
aspirated out from the ULA 384-well plate, 5 µL/384-well of 16 mM UDPGA solution and
the HepaRG medium were added into sample wells and control wells, respectively. The
UGT reaction mixture was added at 10 µL/384-well to all wells including the control wells.
The ULA 384-well plate was incubated in the 5% CO2 incubator at 37C for 2 h, which
was followed by adding 20 µL of reconstituted luciferin detection reagent with D-cysteine
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into all wells and incubated for 20 min at room temperature. Luminescence was measured
using the microtiter plate reader at 560 nm with an integration time of 0.25 - 1 s.
Albumin secretion
Albumin secretion from HepaRG spheroids was measured using human albumin (ALB)
Elisa kit (ThermoFisher). Before performing the assay, all the reagents were brought to
room temperature and prepared according to the manufacturer’s protocol. Supernatants
were collected from the ULA 384-well plate and stored at -80C until use. Samples and
standards were added into appropriate wells of anti-human albumin precoated 96-well strip
plate and incubated for 2.5 h at room temperature with gentle shaking. The 96-well plate
was rinsed with 1x wash buffer and incubated with biotinylated antibody for 1h followed
by washing and incubation with streptavidin-HRP solution for 45 min at room temperature
with gentle shaking. After incubation with streptavidin-HRP solution, 3,3',5,5'tetramethylbenzidine (TMB) substrate was added and incubated for 30 min at room
temperature in the dark with gentle shaking, which was followed by adding the stop
solution. Absorbance was measured with the microtiter plate reader at 450 nm and 550 nm.
The absorbance values at 550 nm was subtracted from the values obtained at 450 nm to
correct for optical imperfections in the microplate.
5.2.7. Compound treatment for metabolism-mediated neurotoxicity
Metabolism-sensitive model compounds including acetaminophen, cyclophosphamide,
and 3,3’-iminodipropionitrile (IDPN) (all from Sigma-Aldrich) were selected to investigate
metabolism-mediated neurotoxicity in the HepaRG and ReNcell VM co-culture system. A
powder form of each compound was dissolved in DMSO to prepare compound stock
solutions. Five concentrations of each compound with 4-fold serial dilution and one
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DMSO-alone control were prepared in HepaRG maintenance medium to obtain dose
response curves and calculate IC50 values. The concentration ranges of the compounds used
were as follows: acetaminophen (0.1 - 25 mM), cyclophosphamide (0.1 - 25 mM), and
IDPN (0.02 - 4 mM). The dosage range of these compounds were selected based on their
known IC50 values obtained from literature. The compounds at five dosages and one control
were dispensed at a volume of 40 µL/well in the ULA 384-well plate containing 7 daycultured HepaRG spheroids. For the assessment of metabolism-mediated neurotoxicity, the
384PillarPlate with 7 day-cultured ReNcell VM was sandwiched with the ULA 384-well
plate containing compounds and HepaRG spheroids, and the sandwiched plates were
incubated for 48 h in the 5% CO2 incubator at 37C (Figure 5.2). As a control, 3D-cultured
ReNcell VM was exposed to the test compounds in the absence of HepaRG spheroids in a
deep-well 384-well plate.
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Figure 5.2. Schematic of experimental procedures for metabolism-mediated
neurotoxicity. Metabolism-induced neurotoxicity of compounds was assessed with 3Dcultured ReNcell VM on the 384PillarPlate coupled with HepaRG spheroids and test
compounds in the ULA 384-well plate. ReNcell VM was encapsulated in 0.75% (w/v)
alginate and 2.5 mg/mL Geltrex and cultured in 3D on the 384PillarPlate for 7 days.
HepaRG cells were incubated for 7 days to form spheroids and maintain high hepatic
functions prior to compound exposure. Compound exposure in the ReNcell VM and
HepaRG co-culture system was performed for 2 days.

5.2.8. Assessment of metabolism-mediated neurotoxicity
Viability of 3D-cultured ReNcell VM on the 384PillarPlate after exposure to metabolites
generated by HepaRG spheroids in the ULA plate was measured by calcein AM staining
for cell membrane integrity. Briefly, a stock solution of 1 M calcein AM was prepared in
DMSO. A final working concentration of the fluorescent dye (0.25 µM calcein AM) was
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obtained by diluting the dye stock solution in the saline solution containing 140 mM of
NaCl and 20 mM of CaCl2 in sterile deionized water. After 48 h compound exposure with
HepaRG spheroids, the 384PillarPlate with 3D-cultured ReNcell VM was rinsed twice for
5 min each by sandwiching it with a 384-well plate containing 50 µL of the saline solution,
followed by staining with 50 µL/384-well of 0.25 µM calcein AM in a 384-well plate for
1 h at room temperature. After 1 h incubation, excess dye in the cell spots was removed by
rinsing it twice with the saline solution in 384-well plates for 10 min. Viability of HepaRG
spheroids in the ULA 384-well plate after compound exposure was measured using the
CellTiter-Glo assay as described above. Green fluorescent images of 3D-cultured ReNcell
VM on the 384PillarPlate were acquired rapidly with the S+ scanner. Exposure times for
the filter channels were adjusted based on histogram to obtain optimum fluorescence
intensity and prevent photobleaching of the fluorescent dye.
5.2.9. Image processing and data analysis
Image processing and data analysis were performed according to the published methods
[131], [223]. Briefly, green fluorescent images obtained from calcein AM staining of
ReNcell VM on the 384PillarPlate were processed using a batch processing macro in
ImageJ for the extraction of fluorescence intensity. The intensity data were plotted using
GraphPad Prism 8 (GraphPad Software, San Diego, CA) to determine the concentrationdependent effect of the test compounds. Since the background fluorescence of completely
dead ReNcell VM (following treatment with 70% methanol for 1 h) was negligible due to
background subtraction, the percentage of live ReNcell VM was calculated using the
following equation:
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% 𝐋𝐢𝐯𝐞 𝐜𝐞𝐥𝐥𝐬 = [

𝑭𝑹𝒆𝒂𝒄𝒕𝒊𝒐𝒏
] 𝐱 𝟏𝟎𝟎
𝑭𝑴𝒂𝒙

where FReaction is the fluorescence intensity of the spot exposed to the compounds and FMax
is the fluorescence intensity of fully viable cells. The fluorescent intensities of all the cell
spots were normalized with respect to the fluorescent intensity of fully viable cells (i.e.,
cell spots in control) to generate sigmoidal dose-response curves with response values
ranging from 0 to 100% plotted against the logarithm of test concentrations. The sigmoidal
dose-response curves and IC50 values (concentration of the compound where 50% of
cellular mechanism is inhibited) were obtained using the following equation:

𝐘 = 𝐁𝐨𝐭𝐭𝐨𝐦 + [

𝑻𝒐𝒑 − 𝑩𝒐𝒕𝒕𝒐𝒎
]
𝟏 + 𝟏𝟎(𝑳𝒐𝒈𝑰𝑪𝟓𝟎 −𝑿)×𝑯

where IC50 is the midpoint of the curve, X is the log concentration of test compound, H is
the hill slope, and Y is the cellular response (% live cells), starting from the top plateau
(Top) of the sigmoidal curve to the bottom plateau (Bottom).
5.2.10. Statistical Analysis
To investigate the effect of compound biotransformation on toxicity, statistical analysis was
performed with GraphPad Prism 8. The data are presented as the means ± standard
deviation (SD). Students’ t-tests were conducted at the same concentration of a test
compound in the presence and absence of HepaRG spheroids. Statistically significant
difference between no HepaRG control and HepaRG test conditions was indicated by * for
p < 0.05 and *** for p < 0.001.
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5.3. Results
5.3.1. Viability of 3D-cultured ReNcell VM and HepaRG spheroids
The viability of ReNcell VM encapsulated in alginate-Geltrex on the 384PillarPlate and
cultured in complete NSC medium was measured at days 1, 4, 7, and 10 with calcein AM
and ethidium homodimer-1 staining. In addition, the viability of 3D-cultured ReNcell VM
was also assessed after 24 h and 72 h of culture in HepaRG maintenance medium. High
viability of ReNcell VM in the mixture of 0.75% (w/v) alginate and 2.5 mg/mL GFR
Matrigel on a regular 384-pillar plate with a flat surface has been reported previously in
chapter 2. Similarly, we have observed high viability of 3D-cultured ReNcell VM in the
mixture of 0.75% (w/v) alginate and 2.5 mg/mL Geltrex on the 384PillarPlate. Formation
of ReNcell VM spheroids on the 384PillarPlate was observed over a period of 10 days as
evidenced by the increased size of spheroids (Figure 5.3A) and the increased fluorescence
intensity from the ReNcell VM images at days 4, 7, and 10 (Figure 5.3C). The greencolored dots represent live cells stained with calcein AM. In addition, the viability of 3Dcultured ReNcell VM was maintained even after 3 days of culture in HepaRG maintenance
medium, demonstrating the similarity in media compositions between the HepaRG
medium and the ReNcell VM medium, and the robustness of 3D-cultured ReNcell VM on
the 384PillarPlate (Figure 5.3B and 5.3D). On the other hand, the viability of HepaRG
spheroids in the ULA plate was measured at day 3 and day 7 with the CellTiter-Glo assay,
which measures the ATP level in the cells. We observed that HepaRG spheroids maintained
high viability in the HepaRG maintenance medium over a period of 1 week (Figure 5.3E).
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Figure 5.3. Viability of 3D-cultured ReNcell VM on the 384PillarPlate and HepaRG
spheroids in the ULA 384-well plate. (A) Pictures of ReNcell VM encapsulated in 0.75%
alginate and 2.5 mg/mL Geltrex on the 384PillarPlate, incubated for 10 days, and stained
with the Live/Dead cell viability assay kit (Scale bar: 500 µm). (B) ReNcell VM viability
assessed after 24 h and 72 h incubation in HepaRG maintenance medium (Scale bar: 500
µm). (C) Changes in green fluorescence intensity in 3D-cultured ReNcell VM over 10
days. (D) Changes in green fluorescence intensity in 3D-cultured ReNcell VM after
incubation for 24 h and 72 h in HepaRG media. (E) Changes in luminescence in HepaRG
spheroids cultured in the ULA 384-well plate over 1 week to determine cell viability.
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5.3.2. Hepatic functions of HepaRG spheroids
HepaRG spheroids in the ULA 384-well plate were tested for several liver functions
including representative DME activities and albumin secretion using commercially
available cell-based assays. Among the most important DMEs, the activity of CYP3A4
was determined by a non-lytic, cell-based P450-Glo assay, which contains a cell-permeable
luminogenic substrate (proluciferin) that is converted to luciferin by intracellular CYP3A4.
Luciferin comes out of the cells, reacts with a luciferin detection reagent (LDR), emits light
which is proportional to the activity of CYP3A4. CYP3A4 activity in HepaRG spheroids
was found to be increased over time at day 5 and 9 in HepaRG maintenance medium as
supported by the increase in luminescence (Figure 5.4A). One of representative Phase II
enzymes, GST activity was also shown to be increased after 5 days of incubation in
HepaRG maintenance medium (Figure 5.4B). The activity of GSTs increased nearly 9fold over a period of 9 days from 1 µmol/mL/min to 9 µmol/mL/min. CDNB has been used
as a substrate of GSTs, which is conjugated with GSH through the thiol group of GSH by
the catalytic activity of GSTs. The GS-CDNB conjugate was detected at 340 nm, and the
rate of absorbance increase was directly proportional to GST activity. GST activity was
expressed as µmol/mL/min, which indicates the amount of GS-CDNB conjugate generated
per min by 1 mL of the reaction solution [273]. Likewise, the activity of UGTs in HepaRG
spheroids increased from day 5 as evidenced by the increase in the consumption of
luminogenic proluciferin substrate at day 5 determined by the UGT-Glo assay (Figure
5.4C). Since proluciferin was converted into glucuronidated luciferin by UGT enzymes in
the presence of UDPGA, there was decrease in luminescence when UGTs were active,
whereas native proluciferin reacted with D-cysteine and emitted strong light after
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conjugation with the luciferin detection reagent. Therefore, the activity of UGTs in
HepaRG spheroids was determined by subtracting the luminescence from the sample with
UDPGA from those without UDPGA.
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Figure 5.4. Representative DME activities in HepaRG spheroids cultured in the ULA
384-well plate. (A) CYP3A4 activity measured with the P450-Glo assay kit from Promega,
(B) GST activity measured with the GST assay kit from Sigma-Aldrich, and (C) UGT
activity measured with the UGT-Glo assay kit from Promega.
In addition, high levels of albumin secretion from HepaRG spheroids were
maintained when measured at day 3 and day 7 (Figure 5.5). This result correlates well with
literature where albumin secretion has been maintained constant over a period of 6 weeks
in HepaRG cells [274]. A human albumin ELISA kit was used to measure the level of
albumin secretion in HepaRG spheroids. The standard curve of albumin was generated by
plotting the average of absorbance difference (i.e., absorbance at 450 nm minus absorbance
at 550 nm) on Y-axis as a function of the concentrations of albumin standard on X-axis
(Figure 5.5A). The albumin standard solutions were prepared by diluting 1200 ng/mL of
albumin with solvent provided in the kit (Assay Diluent C) 2.5-fold serially. The level of
albumin secretion at day 3 and day 7 was determined by the sigmoidal standard curve, and
the maximum detection limit was approximately 3000 ng/mL (Figure 5.5B). These results
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demonstrate the utility of HepaRG spheroids as a metabolically-competent cell model for
investigating metabolism-mediated neurotoxicity in combination with 3D-cultured
ReNcell VM.
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Figure 5.5. The level of albumin secretion by HepaRG spheroids. (A) The sigmoidal
standard curve of albumin obtained by plotting absorbance as a function of albumin
concentration. (B) Albumin secreted by HepaRG spheroids and quantified by the standard
curve.

5.3.3. High-throughput, metabolism-mediated neurotoxicity on the 384PillarPlate
Metabolism-mediated neurotoxicity has been demonstrated using metabolism-sensitive
compounds such as acetaminophen, cyclophosphamide, and IDPN, all of which are known
to be converted into more cytotoxic metabolites in the presence of hepatic DMEs.
Metabolites of the compounds were generated by HepaRG spheroids in the ULA 384-well
plate and tested against 3D-cultured ReNcell VM on the 384PillarPlate by simply
sandwiching the two plates together. The HepaRG maintenance medium was used as a
universal medium to maintain high cell viability during the drug exposure for 48 h. The
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compounds exposed to 3D-cultured ReNcell VM in the absence of HepaRG spheroids were
used as controls. In addition, dose response curves were plotted by normalizing
fluorescence intensity obtained from different concentrations of the compounds with those
from no compound controls. The metabolism effect on 3D-cultured ReNcell VM by the
compounds at the highest concentration due to the presence of metabolically competent
HepaRG spheroids was compared with those from the ReNcell VM alone conditions.
Statistically significant difference was observed between the ReNcell VM-HepaRG case
and the ReNcell VM alone case in terms of metabolism-mediated neurotoxicity.
For example, the viability of ReNcell VM reduced up to 50% when exposed to 25
mM of acetaminophen in the presence of HepaRG spheroids as compared to those in 10%
reduction in the absence of HepaRG spheroids. This difference was statistically significant
(p value < 0.001) when analyzed by Students’ t-test (Figure 5.6A). We hypothesized that
acetaminophen is transformed into its toxic metabolite, NAPQI [275], in the presence of
HepaRG spheroids, which influenced the viability of 3D-cultured ReNcell VM. This
hypothesis was supported by high activity of CYP3A4 in HepaRG spheroids (Figure 5.4A)
and low viability of HepaRG spheroids in the presence of acetaminophen (Figure 5.7 A).
Similarly, the viability of ReNcell VM reduced approximately 40% when exposed to 25
mM of cyclophosphamide in the presence of HepaRG spheroids as compared to those in
15% reduction in the absence of HepaRG spheroids. This difference was statistically
significant (p value < 0.05) (Figure 5.6B). The prodrug, cyclophosphamide, is well known
to be metabolized by CYP450 isoforms including CYP3A4 and CYP2B6 [276]–[278] into
active metabolite, 4-hydroxycyclophosphamide. Therefore, the augmented toxicity of
cyclophosphamide in the presence of HepaRG spheroids in our study correlates well with
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literature where the cytotoxic effect of 4-hydroxycyclophosphamide has been reported by
its metabolism by CYP3A4 [276], [279]. Finally, the viability of ReNcell VM reduced 32%
when exposed to 4 mM of IDPN in the presence of HepaRG spheroids whereas there was
only 8% reduction in the viability of ReNcell VM in the absence of HepaRG spheroids
(Figure 5.6C). This difference was statistically significant (p value < 0.05), thereby
demonstrating the effectiveness of our co-culture system in assessing metabolism-mediated
neurotoxicity of chemicals in high throughput.
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Figure 5.6. Dose response curves of 3D-cultured ReNcell VM on the 384PillarPlate
tested with HepaRG spheroids in the ULA 384-well plate in the presence of test
compounds: (A) acetaminophen, (B) cyclophosphamide, and (C) IDPN. For cell viability,
membrane integrity of 3D-cultured ReNcell VM was measured with calcein AM staining.
* is for p < 0.05 and *** is for p < 0.001.
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Figure 5.7. Dose response curves of HepaRG spheroids in the ULA 384-well plate
tested with the compounds: (A) acetaminophen, (B) cyclophosphamide, and (C) IDPN.
Cell viability was measured by the Cell Titer-Glo assay.
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5.4. Discussion
Assessing the toxicity of parent compounds and their metabolites is of critical importance
in pharmaceutical and chemical industries for safer product development. To investigate
metabolism-mediated effects of potential neurotoxicants in vitro, it requires to incorporate
hepatic cell culture in neural cell culture [272]. Primary hepatocytes and hepatic cell lines
expressing individual or multiple DMEs are primarily used to provide metabolism
competence [271], [280]. In our study, we incorporate HepaRG spheroids due to their
robustness and user friendliness. Although HepaRG cells are derived from tumors of a
female patient suffering from chronic hepatitis C infection and hepatocarcinoma [281]–
[283], they have gained enormous popularity as an in vitro model system in the field of
drug metabolism and toxicology due to its similarity to primary human hepatocytes in
terms of DME gene expressions and liver-specific functions as compared to other cells
lines [270], [282], [284], [285]. For example, HepaRG cells express similar or higher levels
of CYP450 enzymes compared to primary human hepatocytes [270], [274], [283]. CYP450
enzymes, monooxygenases, are a class of DMEs, which play a major role in
biotransformation of various compounds including drug candidates and environmental
chemicals. Since some of their metabolites are more cytotoxic than parent compounds,
CYP450 enzymes are in part responsible for metabolism-induced toxicity [264], [276],
[278]. Among dozens of major isoforms of CYP450s, CYP3A4 alone can metabolize
almost 50% of known therapeutic drugs [286] and is therefore subjected to a wide range of
studies [269], [287], [288]. Formation of reactive metabolites after CYP3A4 metabolism
is a critical issue in drug safety screening [289].
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Increased activities of CYP450s along with GSTs and UGTs in our HepaRG
spheroids correlated well with other HepaRG cell studies where increased expression levels
of DMEs and hepatic functions were observed in 2D monolayer cultures and 3D spheroid
cultures with hepatic cell culture media supplemented with DMSO [270], [274], [282],
[283]. For example, Aninat et al. demonstrated increased expression levels of DMEs with
longer periods of incubation in 2% DMSO-supplemented media [283]. Similarly, in the
study by Hart et al., up-regulation of CYP3A4 and UGTs in HepaRG cells incubated over
a period of 2 weeks in the maintenance medium was observed, which was comparable to
the levels of the enzymes in primary hepatocytes [270]. In addition, Kanebratt and
Andersson showed the increased expression level of CYP3A4 over time in the presence of
2% DMSO [274]. Moreover, albumin secretion from HepaRG spheroids at day 3 and 7 in
this study is comparable to the level of albumin secretion obtained by Wang et al., in their
study with tethered spheroids of HepaRG cells [290]. In our study, the HepaRG
maintenance medium containing DMSO was added after 24 h of HepaRG cell seeding in
the ULA 384-well plate, replacing the thawing and plating media. As a result, increased
activity of DMEs was observed after 72 h of incubation in the maintenance medium.
Metabolism-sensitive compounds including acetaminophen, cyclophosphamide,
and IDPN were selected based on the information of their metabolism by DMEs. For
example, acetaminophen is widely used as an analgesic and antipyretic drug and its
overdose is known to be one of the most common drug-induced liver injuries [1,2].
Acetaminophen is well known to be metabolized by CYP450s into highly reactive and
unstable metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which is primarily
responsible for acetaminophen-induced hepatotoxicity. Detoxification of NAPQI occurs
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through its binding to the sulfhydryl group of GSH to form acetaminophen-glutathione.
However, high dosages of acetaminophen consume intracellular GSH and saturate
glucuronidation reaction mediated by UGTs, both of which are the main mechanism of
liver protection from toxic compounds, resulting in high levels of NAPQI in the hepatic
cells and leading to liver injury [275], [291], [292]. Cyclophosphamide, a widely used
chemotherapeutic drug, is known to have severe side effects and metabolism-induced
toxicity at high dosages in humans when metabolized into 4-hydroxycyclophosphamide by
CYP450s such as CYP3A4 and CYP2B6 [223], [278], [279]. In the study by Yokoyama et
al., HepaRG cell viability was reduced to 57% at 25 mM of cyclophosphamide dosage for
48 h, which was alleviated by co-treatment with 100 µM of 1-aminobenzotriazole, a broad
CYP inhibitor [278]. In our study, statistically significant, metabolism-mediated
hepatoxicity and neurotoxicity were observed at 25 mM of cyclophosphamide dosage,
indicating the effect of the reactive metabolite generated by CYP450s in HepaRG
spheroids. IDPN that produces profound behavioral abnormalities has been widely
explored for its neurotoxic potential in in vivo studies [293]–[295]. It has been known to
be metabolized by DMEs, specifically flavin-containing monooxygenases (FMOs) to
reactive metabolites including N-hydroxy-IDPN that are more neurotoxic than the parent
compound [296], [297]. FMOs have been known to be expressed moderately as compared
to CYP450s in HepaRG cells [270], [284]. We have explored the metabolism-mediated
cytotoxic effect of IDPN with HepaRG spheroids and its downstream effect on 3D-cultured
ReNcell VM on the 384PillarPlate for the first time.
Metabolism-mediated neurotoxicity of xenobiotics has been primarily investigated with
the CYP enzymes locally expressed in brain [288], [298], [299]. However, considering the
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interactions between organs such as liver and brain in the whole organism and its role in
determining the accumulation of xenobiotics in the target organ, a single organ cell culture
might be insufficient to predict the probable toxic effects of drugs in vivo [300]. In
addition, the permeability of metabolites through blood brain barrier (BBB) also needs to
be considered since, the BBB provides the first line of defense against xenobiotics and
regulates the effect of compounds and their metabolites in human brain. The BBB is formed
by specialized endothelial cells lining cerebral micro-vessels characterized by high
electrical resistance, epithelial-like tight junctions that facilitates the uptake of essential
nutrients and efflux of xenobiotics [301], [302]. Thus, understanding the metabolite
penetration of the BBB will be critical in considering the co-culture system for metabolismmediated neurotoxicity. However, modeling the complex interactions between BBB and
other cellular components of the CNS in vitro is a challenging task. Therefore, it is only
recently, that in vitro models with BBB has been considered for neurotoxicity studies. For
example, Koo et al., recently reported a microfluidic 3D brain culture platform consisting
of two membrane-free compartments and an endothelial cell-lined vascular compartment
to take into account the penetration of xenobiotics across BBB [245].
Microfluidic tissue-on-chip platforms possess limitations in terms of its adaptation in highthroughput compound screening. On the other hand, the 384PillarPlate is compatible with
standard 384-well plates and existing HTS equipment and cell imagers. The unique
384PillarPlate platform offers robust, high-throughput, cost-efficient, 3D cell culture for
testing mechanisms of toxicity by various compounds and environmental chemicals.
Individual cell spots or multiple cell spots in layers can be printed accurately on the
384PillarPlate using a microarray bioprinter or manually dispensed using multichannel
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pipettes for tissue engineering and disease modeling. The 384PillarPlate requires relatively
small amounts of cells, hydrogels, extracellular matrices, growth factors, compounds, and
reagents for creating and evaluating bioprinted cells/tissues. Cell image acquisition from
bioprinted cells/tissues is straightforward because the entire sample depth fits within the
focus depth of a normal objective (4x). Although the metabolism-mediated neurotoxicity
testing system established in 384PillarPlate/384-well plate combination in this study did
not consider BBB for the simplicity and high-throughput testing. Multiple cell types can in
fact be cultured in 3D in the ULA 384-well plate and on the 384PillarPlate separately and
combined later for compound tests for relatively short periods of time, which reduces
critical concerns for developing universal media for co-cultures significantly. Moreover,
highly reproducible, high-throughput precision printing allows us to test a variety of cell
culture conditions and individual drugs/mixtures of drugs in combination, which makes it
well suited for early-stage HTS of compound libraries.
5.5. Conclusions
We successfully established a metabolism-mediated neurotoxicity testing system by
combining metabolically competent HepaRG spheroids in the ULA 384-well plate with
3D-cultured neural stem cell line, ReNcell VM on the 384PillarPlate. To the best of our
knowledge, the 384PillarPlate coupled with the ULA 384-well plate is the only system that
can provide a simple and straightforward method to facilitate two organ-organ
communications (e.g., liver metabolism influencing brain developmental toxicity) in high
throughput. This system will require validation with several known neurotoxic and nonneurotoxic compounds for their potential to induce neurotoxicity after biotransformation
accompanied by high-content imaging assays. Overall, the 384PillarPlate can be used as a
125

promising tool for predictive human toxicology in pharmaceutical and chemical industries
with 3D-cultured human cells.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
6.1. Conclusions
Relatively small numbers of commercially available chemicals have been subjected to
international guidelines studies for developmental neurotoxicity, creating a high demand
for evaluating the neurotoxicity potential of drug candidates and industrial chemicals. The
assessment of neurotoxicity and developmental neurotoxicity (DNT) is based on high-dose
animal testing according to OECD test guideline (TG) 426 and TG 443. Adverse effects
on neurodevelopment could also result in altered neuronal cell populations in the absence
of cell death and thus may not be detected by regular cytotoxicity screening. In addition,
there are differences in the brain development of humans and animals, leading to inaccurate
assessment of human health risk based on animal data. Significant efforts have been
exerted towards the development of mechanism-based, in vitro assays using human cells,
particularly after the release of the Tox21 vision document (NRC 2007) in 2007. However,
the majority of existing in vitro systems are still based on 2D cell monolayers which do not
provide physiological relevance required for high predictability of neurotoxicity in vivo.
This dissertation details the methods for creating 3D-cultured NSCs in high-throughput
platforms and demonstrates the feasibility for performing high-throughput neurotoxicity
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assessment to predict the toxicity of unknown chemicals in vivo. In this study, we
successfully established miniaturized 3D-cultured ReNcell VM in biocompatible
hydrogels on multiple high-throughput cell culture platforms and constructed a highlyefficient promoter-reporter assay system for rapid assessment of lineage-specific
differentiation of human NSCs. We further established various high-content imaging (HCI)
assays for the assessment of mechanisms of neurotoxicity and demonstrated rapid
assessment of metabolism-mediated neurotoxicity using 3D-cultured ReNcell VM and
HepaRG spheroids.
The high-throughput neurotoxicity testing system presented in this work can be
implemented in various industrial and academic settings to identify the effects of
therapeutic drug candidates and environmental chemicals in NSC morphology, cell
function, molecular actions on cell surface receptors, and mechanisms of toxicity, thereby
ultimately enhancing the predictability of DNT in vivo. For example, the 3D NSC culture
system combined with recombinant lentiviruses developed in Aim 1 can be used to rapidly
assess the effect of compounds on viability and differentiation of NSCs. The promoterreporter assay system developed in this study enabled efficient measurement of cell
differentiation and self-renewal by simply comparing green and red fluorescence
intensities from the NSCs. The high-throughput ion channel and ABC-transporter assays
established in Aim 2 combined with the HCI assays established in Aim 3 will enable
researchers to rapidly screen the effect of unknown compounds on various morphological
and functional features with high predictability. In addition, our unique demonstration of
metabolism-mediated neurotoxicity in the two 3D cell culture systems enabled
identification of the toxic effect of compounds and their metabolites. The outcomes from
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all the aims can be combined to establish an intensive neurotoxicity testing system with a
battery of tests that can ensure rapid assessment of neurotoxicity in a physiologically
relevant cellular model. We envision that our high-throughput, 3D NSC platform can be
implemented for large-scale screening of drug candidates and environmental toxicants for
their potential in causing DNT. Table 4 summarizes the key findings of each aims.
Table 4. Summary of results from individual aims

•

•

•

•

Aim 1

Aim 2

Aim 3

Demonstrate high
neuronal cell functions
on 3D NSC microarrays
within biomimetic
microenvironments in
high-throughput on the
chip platform
Optimized ReNcell
VM encapsulation
conditions on the
micropillar and
microwell chip
platform
Established
miniaturized 3D
ReNcell VM culture in
alginate-GFR Matrigel
hydrogels with high
NSC viability and
spheroid formation
Constructed
recombinant
lentiviruses with dual
promoters for
measuring transduction
efficiency and NSCspecific biomarkers
Infected ReNcell VM
with recombinant
lentiviruses and
demonstrated high

Establish high-throughput
ion channel and
transporter assays in 3Dcultured NSCs for
neurotoxicity assessment

Establish HCI assays on 3D
NSC microarrays to
investigate mechanistic
profiles of toxicity by
compounds and their
metabolites

•

•

•

•

•

Identified major ion
channels and ABCtransporters expressed
in ReNcell VM via
RNA-Seq
Established 3D NSC
culture on the 384pillar plate for longterm cell culture
Demonstrated high cell
viability and spheroid
formation over 2
months
Established highthroughput potassium
channel and calcium
channel assays in 3Dcultured NSCs with a
high signal-tobackground ratio
Measured the activity
of Kv 7.2, Kv 4.3 and
SOCC in 3D-cultured
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•

•

•

•

•

Optimized the
concentrations of
fluorescent dyes to get a
high signal-to-background
ratio in 3D NSC culture
Established robust and
reproducible HCI assays
in 3D-cultured NSCs to
assess mechanisms of
action of test compounds
Investigated the dosedependent effect of test
compounds and
determined IC50 values
from the dose-response
curves
Identified mitochondrial
impairment as the main
mechanism of toxicity
among the HCI assays
Established 3D NSC
culture on the
384PillarPlate and

•

neuronal functions in
3D NSC culture
Validated the
•
selectivity of
recombinant
lentiviruses with
differentiation inducers

NSCs with specific
inhibitors
Established high•
throughput ABCtransporter assays and
measured the TAF with •
specific inhibitors

HepaRG spheroids in the
ULA 384-well plate
Demonstrated high DME
activities in HepaRG
spheroids
Combined 3D NSC
culture and HepaRG
spheroids for the
assessment of
metabolism-mediated
neurotoxicity with test
compounds

6.2. Future Directions
1. Although cell viability and spheroid formation of NSCs were shown to be increased
in the mixture of alginate and GFR Matrigel/Geltrex, alginate which is an inert
hydrogel did not facilitate cell-ECM interactions. In the future, naturally derived
ECM hydrogels should be considered for 3D cell/organoid culture to achieve high
cell viability and cell-ECM interactions, mimicking the in vivo features.
2. The 3D NSC culture established on the 384PillarPlate platform was a simple proofof-concept system which needs to be improved by developing brain organoids
comprising of all major cell types, including neurons, astrocytes, and
oligodendrocytes, which recapitulate the aspects of human brain development and
function more closely.
3. Various combinations of growth factors and small molecules should be investigated
for efficient differentiation of NSCs into neurons, astrocytes, and oligodendrocytes
and compare the effect of test compounds on differentiation of NSCs.
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4. Gene expression data for major ion channels and ABC-transporters obtained from
RNA-Seq analysis should be validated at protein levels with immunofluorescence
assays or western blots.
5. The effect of unknown compounds on the modulation of ion channels and
transporters, and their influence on physiological functions of 3D-cultured NSCs
such as proliferation, differentiation, and migration should be investigated.
6. We did not investigate the expression of functional ion channels and transporters
in differentiated NSCs (excitable neuronal cells). Future studies should consider
investigating the differentiated cells for the activities of ion channels and
transporters.
7. The HCI assays established in Aim 3.1 need to be validated with a large number of
test compounds including neurotoxic compounds and control compounds with no
known neurotoxicity.
8. Sensitivity and specificity must be calculated to determine the predictivity of the
HCI assays established in Aim 3.1.
9. DNT-specific endpoints such as migration, proliferation, neurite outgrowth,
synapse formation must be included to improve the predictability of in vivo DNT.
10. In Aim 3.2, we established metabolism-mediated neurotoxicity assays with only
three metabolically active test compounds and one assay. To validate the two 3D
cell culture systems and ensure high predictability of metabolism-mediated
neurotoxicity in vivo, a large number of metabolically active compounds along with
control compounds must be tested with multiple DNT-specific endpoints.
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11. Incorporation of microvasculature and blood-brain barrier in in vitro brain organoid
models would enable understanding of the expression of efflux and transporter
proteins and small molecules and the permeability of reactive metabolites to the
brain and provide more accurate predictability of in vivo exposure scenarios.
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APPENDIX

Apart from voltage-gated potassium channels and store-operated calcium channels,
chloride ion channel assays were also investigated on monolayers of ReNcell VM in the
96-well plate using Premo™ halide sensor kit (Thermo Fisher). This assay consists of
baculovirus-mediated gene delivery (BacMam technology) to introduce genes for the
Premo™ halide sensor into the cells and express the corresponding protein. The Premo™
halide sensor is based on a green fluorescent protein (GFP) that is sensitive to iodide ions,
an analog of halide ions. When iodide ions permeate through chloride ion channels, they
react with the Premo™ halide sensor, resulting in a loss of fluorescence emission intensity.
Thus, bright intracellular fluorescence can be observed at an excitation/emission
wavelength of 515/530 nm when chloride ion channels are closed in the presence of
blockers. Similarly, the opening of chloride ion channels with activators can be detected
by measuring decrease in GFP fluorescence.
The expression level of Premo™ halide sensor was optimized on 2D-cultured ReNcell
VM. Briefly, ReNcell VM was seeded in the laminin-coated 96-well plate at 10,000
cell/well and incubated for 24 h prior to infection with varying concentrations of the
baculovirus carrying genes for Premo™ halide sensor. Five different concentrations of the
baculovirus solutions were prepared by mixing the baculovirus stock solution with growth
media at different ratios (10:90, 20:80, 30:70, 40:60, and 50:50), and then 50 µL of the
mixtures were added in the 96-well plate with ReNcell VM monolayers for over 16 h to
allow the expression of Premo™ halide sensor. The optimum ratio of baculovirus to growth
media was determined by analyzing green fluorescent cell images obtained from S+
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Scanner (Figure 1). As a result, the optimum level of Premo™ halide sensor expression
was achieved at the 40:60 ratio of baculovirus to growth media. The opening of chloride
ion channels and subsequent quenching of Premo™ halide sensor was achieved by adding
a stimulus buffer containing sodium iodide (NaI) at a final concentration of 75 mM (Figure
1). The decrease in green fluorescence signals in the cell images indicates the entry of
iodide ions into the cells through chloride ion channels and subsequent reaction with
Premo™ halide sensor.
After determining the optimum transduction condition with the baculovirus, the
Premo™ halide ion channel assay was tested with a chloride ion channel activator,
lubiprostone, on monolayers of ReNcell VM. Briefly, ReNcell VM was seeded in the
laminin-coated 96-well plate at 10,000 cell/well and incubated for 24 h prior to the
baculovirus infection with the 40:60 ratio of baculovirus to growth media. After the
baculovirus infection for over 16 h for expressing the Premo™ halide sensor, the
monolayers of ReNcell VM in the 96-well plate were exposed to 6 different concentrations
of lubiprostone for 30 min. This was followed by adding a stimulus buffer containing 75
mM of sodium iodide and imaging the cells with S+ Scanner. To obtain baseline
fluorescence and investigate the effect of lubiprostone on 2D-cultured ReNcell VM
expressing the Premo™ halide sensor, the pictures were taken before and after stimulation
and the dose response curve was obtained (Figure 2). As expected, dose-dependent
decrease in fluorescence was observed, which indicate that chloride ion channels were
activated with lubiprostone and iodide ions entered through chloride ion channels reacted
with the Premo™ halide sensor, resulting in the quenching of fluorescence.
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(A)
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Figure 1. Optimization of Premo™ halide sensor performed on monolayers of ReNcell
VM in a 96-well plate. ReNcell VM was seeded in the 96-well plate at 10,000 cells/well
and cultured for 24 h prior to infection with recombinant baculovirus carrying genes for
Premo™ halide sensor. Baculovirus solutions were prepared by mixing the baculovirus
stock solution with growth media at different ratios (10:90, 20:80, 30:70, 40:60, and 50:50).
In addition, 50 µL of the mixtures were added in the 96-well plate with ReNcell VM
monolayers and incubated for over 16 h as recommended by the vendor to infect ReNcell
VM and allow the expression of Premo™ halide sensor. (A) Images of baculovirus-infected
ReNcell VM obtained at exposure time of 500 milliseconds. The optimum expression of
Premo™ halide sensor in ReNcell VM was observed at a ratio of 40:60 for baculovirus to
growth media. Scale bar: 100 µm. (B) Images of baculovirus-infected ReNcell VM
obtained after stimulation with a buffer containing sodium iodide (NaI) at 75 mM. The
decrease in fluorescence intensity after stimulation is indicative of the subsequent entry of
iodide ions into the cells. Scale bar: 100 µm.

159

(A)

(B)

Premo Halide quench (%)

100

80

60

40

20
0.01

0.1

1

10

100

1000

Lubiprostone (µM)

Figure 2. Premo™ halide sensor-based chloride channel assay performed on
monolayers of ReNcell VM in a 96-well plate with an activator. ReNcell VM was seeded
in the 96-well plate at 10,000 cells/well and cultured for 24 h prior to infection with
recombinant baculovirus carrying genes for Premo™ halide sensor. A baculovirus solution
was prepared by mixing the baculovirus stock solution with growth media at 40:60 ratio.
In addition, 50 µL of the mixture was added in the 96-well plate with ReNcell VM
monolayers and incubated for over 16 h to infect ReNcell VM and allow the expression of
Premo™ halide sensor. (A) Images of baculovirus-infected ReNcell VM after stimulation
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with a buffer containing sodium iodide (NaI) at 75 mM and exposure to lubiprostone, a
potent chloride channel activator. The decrease in fluorescence intensity after stimulation
and exposure to lubiprostone is indicative of the subsequent entry of iodide ions into the
cells. The black dotted image represents baculovirus-infected ReNcell VM before
stimulation and lubiprostone exposure (control). All images were obtained at exposure time
of 700 milliseconds with S+ Scanner. Scale bar: 100 µm. (B) Decrease in green
fluorescence intensity due to lubiprostone-induced chloride ion channel opening, obtained
from baculovirus-infected ReNcell VM in the 96-well plate. Scale bar: 100 µm.
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